

Supporting Information

Exploiting a Novel Size Exclusion Phenomenon for Enantioselective Acid / Base Cascade Catalysis

Michael E. Muratore,[‡] Lei Shi,[‡] Adam W. Pilling,[†] R. Ian Storer,^Ω and Darren J. Dixon^{‡*}

[‡] *Department of Chemistry, Chemistry Research Laboratory, University of Oxford, Mansfield Road, Oxford, OX1 3TA, UK,* [†] *School of Chemistry, The University of Manchester, Oxford Road, Manchester, Lancashire, M13 9PL, UK,* ^Ω *Pfizer Neusentis, The Portway Building, Granta Park, Cambridge, CB21 6GS, UK*

1.	General Information	- 4 -
2.	Preparation of starting materials	- 5 -
2.1.	Preparation of substituted tryptamines 13	- 5 -
2.1.1.	General procedure A for the preparation of substituted indoles 10	- 5 -
2.1.2.	General procedure B for the preparation of substituted indole-3-carbaldehydes 11	- 7 -
2.1.3.	General procedure C for the preparation of substituted indole nitro-olefins 12	- 8 -
2.1.4.	General procedure D for the preparation of substituted tryptamines 13	- 9 -
2.2.	Preparation of pro-nucleophiles 6	- 11 -
2.2.1.	General procedure E for the preparation of malonate monoamides 14	- 11 -
2.2.2.	General procedure F for the preparation of pro-nucleophiles 6	- 15 -
2.3.	Preparation and characterisation of dimethyl {[2-(1<i>H</i>-indol-3-yl)ethyl] carbamoyl}(3-oxobutyl)malonate 8a (substrate for optimisation)	- 20 -
3.	Proof of principle for the site-isolated PS-BEMP and bulky BPA catalysed Michael addition/enantioselective <i>N</i>-acyliminium cyclisation cascade	- 21 -
4.	Titration experiments	- 21 -
5.	NMR conversions of 6a into 8a in the presence of 10 mol % of PS-BEMP and varying amounts of acid 3	- 23 -
6.	Optimisation of the enantioselective <i>N</i>-acyliminium cyclisation	- 25 -
7.	Optimisation of the base and acid catalysed tandem Michael addition / enantioselective <i>N</i>-acyliminium cyclisation of 6a into 9a	- 26 -

8. General procedure G for the base-catalysed Michael addition / acid-catalysed enantioselective <i>N</i>-acyliminium cyclisation cascade	- 26 -
References	- 37 -
NMR spectra of indole 10a	- 38 -
NMR spectra of indole 10b	- 39 -
NMR spectra of 7-methyl indole-3-carbaldehyde 11a	- 40 -
NMR spectra of indole nitro-olefin 12a	- 41 -
NMR spectra of indole nitro-olefin 12b	- 42 -
NMR spectra of tryptamine 13c	- 43 -
NMR spectra of tryptamine 13d	- 44 -
NMR spectra of malonate monoamide 14a	- 45 -
NMR spectra of malonate monoamide 14b	- 46 -
NMR spectra of malonate monoamide 14c	- 47 -
NMR spectra of malonate monoamide 14d	- 48 -
NMR spectra of malonate monoamide 14e	- 49 -
NMR spectra of malonate monoamide 14f	- 50 -
NMR spectra of malonate monoamide 14g	- 51 -
NMR spectra of pro-nucleophile 6a	- 52 -
NMR spectra of pro-nucleophile 6b	- 53 -
NMR spectra of pro-nucleophile 6c	- 54 -
NMR spectra of pro-nucleophile 6d	- 55 -
NMR spectra of pro-nucleophile 6e	- 56 -
NMR spectra of pro-nucleophile 6f	- 57 -
NMR spectra of pro-nucleophile 6g	- 58 -
NMR spectra of oxoamide 8a (substrate for optimisation)	- 59 -
NMR spectra and HPLC traces of β-carboline 9a	- 60 -
NMR spectra and HPLC traces of β-carboline 9b	- 63 -
NMR spectra and HPLC traces of β-carboline 9c	- 66 -
NMR spectra and HPLC traces of β-carboline 9d	- 69 -
NMR spectra and HPLC traces of β-carboline 9e	- 72 -
NMR spectra and HPLC traces of β-carboline 9f	- 75 -
NMR spectra and HPLC traces of β-carboline 9g	- 78 -

NMR spectra and HPLC traces of β-carboline 9h	- 81 -
NMR spectra and HPLC traces of β-carboline 9i	- 84 -
NMR spectra and HPLC traces of β-carboline 9j	- 87 -

1. General Information

All reactions were performed in open, round-bottom flasks, unless otherwise stated. Solvents were used as purchased unless otherwise stated. Commercial reagents were used as purchased without any further purification.


Organic solutions were concentrated under reduced pressure on a Büchi rotary evaporator. Chromatographic purification of products was carried out using Merck Kieselgel 60 silica gel (230-400 mesh). Thin-layer chromatography was carried out using Merck Kieselgel 60 F₂₅₄ (230-400 mesh) fluorescent treated silica which were visualized under UV light (254 nm) or by staining with an aqueous potassium permanganate solution or a *para*-anisaldehyde alcoholic solution.

¹H NMR spectra were recorded in deuterated solvents on Bruker 500 or 400 spectrometers, at 500 or 400 MHz, with residual protic solvent as the internal standard. ¹³C NMR spectra were recorded in deuterated solvents on Bruker 500 or 400 spectrometers, at 125 or 100 MHz, with the central peak of the deuterated solvent as the internal standard. Chemical shifts (δ) are given in parts per million (ppm), and coupling constants (J) are given in Hertz (Hz) rounded to the nearest 0.5 Hz. The ¹H NMR spectra are reported as δ /ppm downfield from tetramethylsilane (multiplicity, number of protons, assignment, coupling constant J /Hz). The ¹³C NMR spectra are reported as δ /ppm. Assignments are aided by the use of DEPT-135, COSY, HMQC and HMBC spectra where necessary. IR spectra were recorded on a Bruker Tensor 27 FT-IR spectrometer, from a thin film deposited on a sodium chloride plate and only diagnostic absorbances (λ_{max}) are reported (OOP = bending out of plan). Low resolution mass spectra were recorded on a Waters LCT premier XE mass spectrometer. High resolution mass spectra were recorded on a Bruker MicroTof mass spectrometer (ESI); in the particular cases where electrospray ionisation was not a suitable technique, chemical ionisation was used and high resolution mass spectra were recorded on a Micromass GCT. Enantiomeric excesses were determined using high performance liquid chromatography (HPLC) performed on an Agilent Technology 1200 Series system (column and solvent conditions are given with the compound). Melting points were recorded on a Leica Galen III apparatus, at ambient pressure and are uncorrected. Optical rotations were recorded using a Perkin-Elmer 241 polarimeter; specific rotation (SR) ($[\alpha]_D$) are reported in 10⁻¹ deg.cm².g⁻¹; concentrations (c) are quoted in g/100 mL; D refers to the D-line of sodium (589 nm); Temperatures (T) are given in degrees Celsius (°C).


All atom numbering used in this section is arbitrary and does not follow any particular convention.

2. Preparation of starting materials

2.1. Preparation of substituted tryptamines 13



2.1.1. General procedure A for the preparation of substituted indoles 10




According to a modified literature procedure.¹

The desired *ortho*-substituted nitro benzene substrate (1 equivalent) was dissolved in anhydrous tetrahydrofuran (4 mL per mmol of substrate) in a dry flask under nitrogen. The solution was cooled to $-40\text{ }^{\circ}\text{C}$ and a 1M solution of vinylmagnesium bromide in tetrahydrofuran was added quickly to the vigorously stirred solution, at $-40\text{ }^{\circ}\text{C}$. The dark brown mixture was left stirring for 1 hour at $-40\text{ }^{\circ}\text{C}$ and then quenched by the addition of a saturated aqueous solution of ammonium chloride (at $-40\text{ }^{\circ}\text{C}$, 3 mL per 1 mmol). The suspension was then allowed to warm to room temperature and stirred vigorously for 5 minutes. Ethyl acetate (2 mL per 1 mmol) was added and the organic layer separated. The aqueous layer was re-extracted with ethyl acetate ($4 \times 1\text{ mL}$ per 1 mmol). The combined organic extracts were dried over magnesium sulphate and concentrated under reduced pressure. The brown residue was purified by column chromatography on silica gel eluting with petroleum ether/ethyl acetate 95:5 to 9:1.

Preparation and characterisation of 7-methyl-1*H*-indole 10a


The title compound was synthesised according to general procedure A, on a 90.0 mmol scale (12.4 g of 2-nitrotoluene) and isolated as a pale brown solid (4.0 g, 34%). Analytical data in agreement with the literature.²



m.p. 69-72 °C (lit.¹ 80-82 °C); **FT-IR** $\nu_{\max}$ (NaCl) 3402 cm^{-1} (N-H), 1590 cm^{-1} (ArC=C), 1340 cm^{-1} (CH_3), 782 cm^{-1} (ArC-H OOP), 722 cm^{-1} (ArC-H OOP); **^1H NMR** (CDCl_3 , 400 MHz) δ_{H} 2.28 (s, 3H, H-8), 6.52 (app. dd, 1H, H-2, J 3.0 Hz, 2.5 Hz), 6.81 (t, 1H, H-1, J 3.0 Hz), 7.00 (d, 1H, Ar-H, J 7.0 Hz), 7.09 (t, 1H, H-5, J 7.5 Hz), 7.45 (br s, 1H, NH), 7.54 (d, 1H, Ar-H, J 7.5 Hz); **^{13}C NMR** (CDCl_3 , 100 MHz) δ_{C} 16.3 (C-8), 102.5 (C-2), 118.2 (Ar- $\underline{\text{CH}}$), 119.8 (C-5), 120.2 (C-7), 122.2 (Ar- $\underline{\text{CH}}$), 124.0 (C-1), 127.1 (C-3), 135.1 (C-9); **m/z** (ES⁻) 130 ($[\text{M}-\text{H}]^-$, 30%), **HRMS** (ES⁻) exact mass calculated for $[\text{M}-\text{H}]^-$ ($\text{C}_9\text{H}_8\text{N}^-$) requires m/z 130.0662, found m/z 130.0661.


Preparation and characterisation of 7-ethyl-1*H*-indole 10b

The title compound was synthesised according to general procedure A, on a 50.0 mmol scale (7.56 g of 1-ethyl-2-nitrobenzene) and isolated as a pale yellow oil (3.0 g, 41%). Analytical data in agreement with previous report.³



FT-IR $\nu_{\max}$ (NaCl) 3420 cm^{-1} (N-H), 2966 cm^{-1} (C-H), 1608 cm^{-1} (C=C), 1590 cm^{-1} (C=C), 1431 cm^{-1} (CH_2), 1342 cm^{-1} (CH_3), 728 cm^{-1} (ArC-H OOP); **^1H NMR** (CDCl_3 , 400 MHz) δ_{H} 1.49 (t, 3H, H-9, J 7.5 Hz), 2.93 (q, 2H, H-8, J 7.5 Hz), 6.72 (app. dd, 1H, H-2, J 3.0 Hz, 2.0 Hz), 7.17-7.23 (m, 2H, H-1, Ar-H), 7.28 (t, 1H, H-5, J 7.5 Hz), 7.70 (d, 1H, Ar-H, J 8.0 Hz), 7.98 (br s, 1H, NH); **^{13}C NMR** (CDCl_3 , 100 MHz) δ_{C} 13.7 (C-9), 23.9 (C-8), 102.8 (C-2), 118.3 (Ar- $\underline{\text{CH}}$), 120.0 (C-5), 120.3 (Ar- $\underline{\text{CH}}$), 123.8 (C-1), 126.4 (Ar-Cquat.), 127.5 (Ar-Cquat.), 134.5 (C-10); **HRMS** (CI⁺) exact mass calculated for $[\text{M}+\text{H}]^+$ ($\text{C}_{10}\text{H}_{12}\text{N}^+$) requires m/z 146.0970, found m/z 146.0966.


2.1.2. General procedure B for the preparation of substituted indole-3-carbaldehydes 11



Phosphorus oxychloride (1.2 equivalents) was added dropwise to dimethyl formamide (4.4 equivalents) with ice-bath cooling. The mixture was stirred for 1.5 hours, then the chosen indole **10** (1 equivalent) was added as a dimethyl formamide solution (0.5 mL per 1 mmol of indole). The mixture was then allowed to warm to room temperature and stirred for 10 minutes (the mixture became a heavy suspension that required vigorous stirring). 3.8 M aqueous potassium hydroxide (10 equivalents) was added *via* a dropping funnel and after addition the mixture was heated to 105 °C for 1 hour. It was cooled to room temperature before adding saturated aqueous ammonium chloride (5 mL per 1 mmol of indole) and ethyl acetate (10 mL per 1 mmol of indole). The aqueous layer was re-extracted with ethyl acetate (4 × 5 mL per 1 mmol of indole) and the combined organic layers were dried over sodium sulphate, filtered and concentrated *in vacuo* to furnish the desired aldehyde that was further purified by column chromatography on short-path silica gel column.


Preparation and characterisation of 7-methyl-1*H*-indole-3-carbaldehyde 11a

The title compound was prepared according to general procedure **B**, on a 30 mmol scale and isolated after chromatography eluting with dichloromethane/acetone 9:1 to 3:1 as a pale brown solid (82% yield, 3.91 g). Analytical data in agreement with the literature.⁴




m.p. 209-211 °C; **FT-IR** ν_{max} (NaCl) 3243 cm^{-1} (N-H), 1649 cm^{-1} (C=O); **¹H NMR** (d_6 -acetone, 400 MHz) δ_{H} 2.54 (s, 3H, H-8), 7.09 (d, 1H, Ar-H, *J* 7.5 Hz), 7.16 (t, 1H, H-5, *J* 7.5 Hz), 8.07 (d, 1H, Ar-H, *J* 7.5 Hz), 8.16 (d, 1H, H-1, *J* 3.0 Hz), 10.03 (s, 1H, C(O)H), 11.18 (br s, 1H, NH); **¹³C NMR** (d_6 -acetone, 100 MHz) δ_{C} 16.8 (C-8), 119.8 (Ar-CH), 120.5 (Ar-Cquat.), 122.4 (Ar-Cquat.), 123.3 (C-5), 125.1 (Ar-CH), 125.2 (Ar-Cquat.), 137.6 (C-1), 185.4 (C=O); ***m/z*** (ES⁻) 158 ([M-H]⁻, 100%), **HRMS** (ES⁺) exact mass calculated for [M+H]⁺ (C₁₀H₁₀NO⁺) requires *m/z* 160.0757, found *m/z* 160.0758.

Preparation of 7-ethyl-1H-indole-3-carbaldehyde **11b**



The title compound was prepared according to general procedure **B**, on a 24.1 mmol scale and used without further purification in the next reaction (3.50 g, 84% yield crude).


2.1.3. General procedure C for the preparation of substituted indole nitro-olefins **12**



Indole-3-carbaldehyde **11** (1 equivalent) was suspended in nitromethane (2.5 mL per 1 mmol of aldehyde). Dry ammonium acetate (0.7 equivalents) was added to the vigorously stirred suspension. The mixture was heated at reflux for 1-5 hours (disappearance of the starting material monitored by ^1H NMR) and the reaction was stopped immediately after full consumption. The solvent was removed under reduced pressure and the residue partitioned between water (5 mL per 1 mmol) and ethyl acetate (20 mL per 1 mmol). The aqueous layer was re-extracted with ethyl acetate (4×10 mL per 1 mmol) and the combined organics dried over magnesium sulphate, filtered and concentrated *in vacuo*. The residue was purified by short-path silica gel column chromatography.

Preparation and characterisation of 7-methyl-3-[(E)-2-nitrovinyl]-1H-indole **12a**

The title compound was synthesised according to general procedure **C** on a 25 mmol scale and was obtained as an orange solid after purification by short-path silica gel column chromatography eluting with dichloromethane (4.95 g, 98%).




m.p. 226-230 °C (dec.); **FT-IR** ν_{max} (NaCl) 3263 cm^{-1} (N-H), 1611 cm^{-1} (C=C), 1587 cm^{-1} (C=C), 1522 cm^{-1} (NO_2), 1301 cm^{-1} (NO_2); **^1H NMR** (d_6 -acetone, 400 MHz) δ_{H} 2.54 (s, 3H, H-10), 7.11 (d, 1H, Ar-H, J 7.0 Hz), 7.20 (t, 1H, H-7, J 7.5 Hz), 7.76 (d, 1H, Ar-H, J 8.0 Hz), 7.89 (d, 1H, H-4, J 13.5 Hz), 8.11 (d, 1H, H-1, J 3.0 Hz), 8.36 (d, 1H, H-3, J 13.5 Hz), 11.24 (br s, 1H, NH); **^{13}C NMR** (d_6 -acetone, 100 MHz) δ_{C} 16.8 (C-10), 110.0 (C-2), 118.9 (Ar-CH),

123.0 (Ar-Cquat.), 123.1 (C-7), 125.1 (Ar-CH), 125.6 (Ar-Cquat.), 132.7 (C-4), 134.8 (C-3), 135.3 (C-1), 138.3 (C-11); **m/z** (ES+) 225 ([M+Na]⁺, 100%), **HRMS** (ES+) exact mass calculated for [M+Na]⁺ (C₁₁H₁₀N₂O₂Na⁺) requires **m/z** 225.0634, found **m/z** 225.0636.


Preparation and characterisation of 7-ethyl-3-[(E)-2-nitrovinyl]-1H-indole **12b**

The title compound was synthesised according to general procedure C on a 19 mmol scale (theoretical) and was obtained as an orange solid after purification by short-path silica gel column chromatography eluting with dichloromethane (2.50 g, 60% over 2 steps).



m.p. 203-206 °C; **FT-IR** ν_{max} (NaCl) 3333 cm⁻¹ (N-H), 1615 cm⁻¹ (C=C), 1553 cm⁻¹ (C=C), 1523 cm⁻¹ (NO₂), 1302 cm⁻¹ (NO₂); **¹H NMR** (d₄-MeOD, 500 MHz) δ_{H} 1.32 (t, 3H, H-11, *J* 7.5 Hz), 2.91 (q, 2H, H-10, *J* 7.5 Hz), 7.11 (d, 1H, H-8, *J* 7.5 Hz), 7.21 (t, 1H, H-7, *J* 7.5 Hz), 7.63 (d, 1H, H-6, *J* 8.0 Hz), 7.86 (d, 1H, H-4, *J* 13.0 Hz), 7.89 (app. s, 1H, H-1), 8.37 (d, 1H, H-3, *J* 13.0 Hz); **¹³C NMR** (d₄-MeOD, 125 MHz) δ_{C} 14.9 (C-11), 25.0 (C-10), 110.4 (C-2), 118.9 (C-6), 123.5 (2 signals, C-7, C-8), 126.2 (C-5), 129.8 (C-9), 132.4 (C-4), 135.8 (2C, C-1, C-3), 138.0 (C-12); **m/z** (ES+) 239 ([M+Na]⁺, 100%), **HRMS** (ES+) exact mass calculated for [M+Na]⁺ (C₁₂H₁₂N₂O₂Na⁺) requires **m/z** 239.0791, found **m/z** 239.0788.

2.1.4. General procedure D for the preparation of substituted tryptamines **13**



Under a nitrogen inert atmosphere, a tetrahydrofuran solution (10 mL per 1 mmol of nitro olefin) of nitro olefin **12** (1 equivalent) was added to a stirred slurry of lithium aluminium hydride powder (6 equivalents) in tetrahydrofuran (equal volume) at 0 °C. The mixture was allowed to warm to room temperature and stirred for 36 hours. The reaction was quenched by dropwise addition of water until effervescence ceased. The mixture was then diluted with diethyl ether before addition of a saturated aqueous solution of Rochelle's salt and the subsequent biphasic mixture was stirred for 24 hours. The layers were separated and the organic layer was extracted with 1 M aqueous hydrochloric acid. The aqueous phase was basified with 3 M aqueous potassium hydroxide, extracted with diethyl ether,


dried over sodium sulphate, filtered and concentrated *in vacuo* to furnish the desired tryptamine which required no further purification.

Remark: the work-up can be simplified by using sodium sulphate decahydrate to quench the excess LAH. Na₂SO₄·10H₂O was added slowly by portion until $\approx$ 2.5 g of salt was added per 1 g of LAH used. The mixture was then stirred vigorously for 6 hours (colour faded to pale yellow / colourless) and the suspension filtered over celite. The flask and resulting cake were washed thoroughly with diethyl ether (volume identical to tetrahydrofuran used) and then dichloromethane (volume identical to tetrahydrofuran used). The combined organics were concentrated to afford the desired tryptamine that did not require further purification.

N.B. Tryptamine (**13a**) was purchased from Aldrich and used without further purification. 5-bromo tryptamine (**13b**) was prepared as previously described.⁵


Preparation and characterisation of 2-(7-methyl-1H-indol-3-yl)ethanamine **13c**

The title compound was synthesised according to general procedure **D** on a 24 mmol scale and was isolated as a brown gum that was used without further purification (4.14 g, 99%).



FT-IR $\nu_{\max}$ (NaCl) 3338 cm⁻¹ (N-H), 3286 cm⁻¹ (N-H), 1588 cm⁻¹ (C=C), 741 cm⁻¹ (ArC-H OOP); **¹H NMR** (d₆-DMSO, 400 MHz) δ_{H} 2.44 (s, 3H, H-10), 2.88 (br s, 4H, H-3, H-4), 6.84 (br s, 2H, 2 $\times$ Ar-H), 7.13 (br s, 1H, H-1), 7.35 (br s, 1H, Ar-H), 10.84 (br s, 1H, NH indole); **¹³C NMR** (d₆-DMSO, 100 MHz) δ_{C} 16.8 (C-10), 27.7 (C-3), 41.8 (C-4), 112.3 (C-2), 116.0 (Ar-CH), 118.4 (Ar-CH), 120.5 (C-9), 121.4 (Ar-CH), 122.6 (C-1), 126.9 (C-5), 135.9 (C-11); **m/z** (ES⁻) 173 ([M-H]⁻, 100%), **HRMS** (ES⁻) exact mass calculated for [M-H]⁻ (C₁₁H₁₃N₂) requires **m/z** 173.1084, found **m/z** 173.1077.

Preparation and characterisation of 2-(7-ethyl-1H-indol-3-yl)ethanamine **13d**




The title compound was synthesised according to general procedure **D** on a 11.6 mmol scale and was isolated as a pale brown solid that was used without further purification (2.20 g, 99%).


m.p. 203-205 °C (dec.); **FT-IR** $\nu_{\max}$ (NaCl) 3398 cm⁻¹ (N-H), 3282 cm⁻¹ (N-H), 1586 cm⁻¹ (C=C), 1473 cm⁻¹ (CH₂), 743 cm⁻¹ (ArC-H OOP); **¹H NMR**

(d₆-DMSO, 400 MHz) δ_{H} 1.26 (t, 3H, H-11, J 7.5 Hz), 2.86 (q, 2H, H-10, J 7.5 Hz), 3.07 (app. s, 4H, H-3, H-4), 6.88-6.98 (m, 2H, H-7, Ar-H), 7.24 (d, 1H, H-1, J 2.5 Hz), 7.42 (d, 1H, Ar-H, J 7.5 Hz), 11.05 (br s, 1H, NH indole); ^{13}C NMR (d₆-DMSO, 100 MHz) δ_{C} 14.5 (C-11), 23.3 (C-10), 23.8 (C-3), 39.3 (C-4), 110.1 (C-2), 115.9 (Ar-CH), 118.8 (Ar-CH), 118.9 (Ar-CH), 123.1 (C-1), 126.8 (Ar-Cquat.), 127.1 (Ar-Cquat.), 135.1 (C-12); m/z (ES[−]) 223 ([M+Cl][−], 35%), HRMS (ES[−]) exact mass calculated for [M+Cl][−] (C₁₂H₁₆N₂Cl[−]) requires m/z 223.1007, found m/z 223.1001.

2.2. Preparation of pro-nucleophiles 6



2.2.1. General procedure E for the preparation of malonate monoamides 14




Prepared *via* a slight modification of a literature procedure.⁶

A tryptamine derivative **13** (1 equivalent) was suspended in the corresponding neat malonate (5 equivalents). The suspension was heated at 65 °C for 48 to 96 hours. The brown viscous solution was loaded on silica gel and the mixture was eluted with petroleum ether/ethyl acetate to afford the desired dicarbonyl **14**.

Preparation and characterisation of methyl 3-{[2-(1*H*-indol-3-yl)ethyl]amino}-3-oxopropanoate **14a**

Synthesised according to general procedure **E** on 30 mmol scale of **13a** (4.8 g). Purified by column chromatography eluting with petroleum ether/ethyl acetate 2:1 to 2:3 to give the title compound as a pale yellow solid (5.75 g, 74%). Analytical data in agreement with the literature.⁷




m.p. 105-108 °C; **FT-IR** ν_{max} (NaCl) 3353 cm^{-1} (br with shoulder, N-H), 1734 cm^{-1} (C=O ester), 1652 cm^{-1} (C=O amide), 742 cm^{-1} (ArC-H OOP); **¹H NMR** (CDCl₃, 400 MHz) δ_{H} 3.02 (t, 2H, H-3, *J* 7.0 Hz), 3.29 (s, 2H, H-6), 3.65 (app. q, 2H, H-4, *J* 7.0 Hz), 3.70 (s, 3H, H-8), 7.04 (br s, 1H, NH amide), 7.08 (d, 1H, H-1, *J*

2.5 Hz), 7.14 (t, 1H, H-11, *J* 7.5 Hz), 7.22 (t, 1H, H-12, *J* 7.5 Hz), 7.39 (d, 1H, H-13, *J* 7.5 Hz), 7.62 (d, 1H, H-10, *J* 7.5 Hz), 8.09 (br s, 1H, NH indole); **¹³C NMR** (CDCl₃, 100 MHz) δ_{C} 25.1 (C-3), 40.0 (C-4), 41.2 (C-6), 52.3 (C-8), 111.3 (C-13), 112.6 (C-2), 118.6 (C-12), 119.3 (C-11), 122.0 (C-10), 122.1 (C-1), 127.3 (C-9), 136.4 (C-14), 164.9 (C-5), 169.7 (C-7); ***m/z*** (ES⁺) 283 ([M+Na]⁺, 100%), **HRMS** (ES⁺) exact mass calculated for [M+Na]⁺ (C₁₄H₁₆N₂O₃Na⁺) requires *m/z* 283.1053, found *m/z* 283.1063.

Preparation and characterisation of methyl 3-{[2-(5-bromo-1*H*-indol-3-yl)ethyl]amino}-3-oxopropanoate **14b**

Synthesised according to general procedure **E** on 8.4 mmol scale of **13b** (2.0 g). Purified by column chromatography on silica gel eluting with petroleum ether/ethyl acetate 4:1 to 3:2 to give the title compound as a pale yellow oil (2.0 g, 70%).




FT-IR ν_{max} (NaCl) 3303 cm^{-1} (br with shoulder, N-H), 1738 cm^{-1} (C=O ester), 1654 cm^{-1} (C=O amide), 754 cm^{-1} (ArC-H OOP); **¹H NMR** (CDCl₃, 400 MHz) δ_{H} 2.95 (t, 2H, H-3, *J* 7.0 Hz), 3.30 (s, 2H, H-6), 3.60 (app. q, 2H, H-4, *J* 7.0 Hz), 3.70 (s, 3H, H-8), 7.06 (s, 1H, H-1), 7.15 (br s, 1H, NH amide), 7.24 (d,

1H, H-13, *J* 8.5 Hz), 7.27 (dd, 1H, H-12, *J* 8.5 Hz, 1.5 Hz), 7.72 (d, 1H, H-10, *J* 1.5 Hz), 8.33 (br s, 1H, NH indole); **¹³C NMR** (CDCl₃, 100 MHz) δ_{C} 24.9 (C-3), 39.9 (C-4), 40.9 (C-6), 52.4 (C-8), 112.6 & 112.7 (C-2 & C-11), 112.7 (Ar-CH), 121.3 (C-10), 123.3 (C-1), 124.9 (Ar-CH), 129.1 (C-9), 134.9

(C-14), 164.9 (C-5), 169.8 (C-7); **m/z** (ES⁻) 337, 339 ([M-H]⁻, 100%), **HRMS** (ES⁺) exact mass calculated for [M+Na]⁺ (C₁₄H₁₅N₂O₃BrNa⁺) requires **m/z** 361.0158, found **m/z** 361.0161.

Preparation and characterisation of methyl 3-{[2-(7-methyl-1*H*-indol-3-yl)ethyl]amino}-3-oxopropanoate **14c**

Synthesised according to general procedure **E** on 10.0 mmol scale of **13c** (1.74 g). Purified by column chromatography on silica gel eluting with petroleum ether/ethyl acetate 3:1 to 1:2 to give the title compound as a pale brown crystalline solid (1.9 g, 69%).




m.p. 106-108 °C; **FT-IR** ν_{max} (NaCl) 3387 cm⁻¹ (N-H), 3301 cm⁻¹ (N-H), 1739 cm⁻¹ (C=O ester), 1656 cm⁻¹ (C=O amide); **¹H NMR** (CDCl₃, 400 MHz) δ_{H} 2.49 (s, 3H, H-14), 3.01 (t, 2H, H-3, *J* 7.0 Hz), 3.25 (s, 2H, H-6), 3.63 (app. q, 2H, H-4, *J* 7.0 Hz), 3.69 (s, 3H, H-8), 7.00-7.15 (m, 4H, 2 × Ar-H, H-1, NH amide), 7.48 (d,

1H, Ar-H, *J* 7.5 Hz), 8.62 (br s, 1H, NH indole); **¹³C NMR** (CDCl₃, 100 MHz) δ_{C} 16.6 (C-14), 25.2 (C-3), 40.1 (C-4), 41.7 (C-6), 52.4 (C-8), 113.0 (C-2), 116.3 (Ar-CH), 119.6 (Ar-CH), 120.6 (C-13), 122.0 (Ar-CH), 122.6 (Ar-CH), 126.9 (C-9), 136.0 (C-15), 165.1 (C-5), 169.6 (C-7); **m/z** (ES⁺) 297 ([M+Na]⁺, 100%), **HRMS** (ES⁺) exact mass calculated for [M+Na]⁺ (C₁₅H₁₈N₂O₃Na⁺) requires **m/z** 297.1210, found **m/z** 297.1207.

Preparation and characterisation of methyl 3-{[2-(7-ethyl-1*H*-indol-3-yl)ethyl]amino}-3-oxopropanoate **14d**

Synthesised according to general procedure **E** on a 5.85 mmol scale of **13d** (1.1 g). Purified by column chromatography on silica gel eluting with diethyl ether to diethyl ether/ethyl acetate 3:1 to give the title product as a pale brown oil (1.2 g, 71%).




FT-IR ν_{max} (NaCl) 3383 cm⁻¹ (N-H), 3310 cm⁻¹ (N-H), 1741 cm⁻¹ (C=O ester), 1659 cm⁻¹ (C=O amide), 751 cm⁻¹ (ArC-H OOP); **¹H NMR** (CDCl₃, 400 MHz) δ_{H} 1.37 (t, 3H, H-15, *J* 7.5 Hz), 2.87 (q, 2H, H-14, *J* 7.5 Hz), 3.01 (t, 2H, H-3, *J* 7.0 Hz), 3.28 (s, 2H, H-6), 3.64 (app. q, 2H, H-4, *J* 6.5 Hz), 3.70 (s, 3H, H-8), 7.03-7.13 (m,

4H, H-1, 2 × Ar-H, NH amide), 7.47 (dd, 1H, Ar-H, *J* 7.5 Hz, 1.0 Hz), 8.28 (br s, 1H, NH indole); **¹³C NMR** (CDCl₃, 100 MHz) δ_{C} 13.8 (C-15), 23.9 (C-14), 25.1 (C-3), 39.9 (C-4), 41.2 (C-6), 52.3 (C-8),

113.1 (C-2), 116.3 (Ar-CH), 119.7 (Ar-CH), 120.6 (Ar-CH), 121.7 (Ar-CH), 126.7 (Ar-Cquat.), 127.0 (Ar-Cquat.), 135.2 (Ar-Cquat.), 164.9 (C-5), 169.6 (C-7); **m/z** (ES⁻) 287 ([M-H]⁻, 100%), **HRMS** (ES⁺) exact mass calculated for [M+Na]⁺ (C₁₆H₂₀N₂O₃Na⁺) requires **m/z** 311.1366, found **m/z** 311.1366.

Preparation and characterisation of ethyl 3-{[2-(1*H*-indol-3-yl)ethyl]amino}-3-oxopropanoate **14e**


Synthesised according to general procedure E on a 30 mmol scale of **13a** (4.8 g). Purified by column chromatography eluting with petroleum ether/ethyl acetate 2:1 to 1:2 to give the title product as a pale yellow oil (6.0 g, 73%). Analytical data in agreement with previous report.⁷



FT-IR $\nu_{\max}$ (NaCl) 3393 cm⁻¹ (N-H), 3309 cm⁻¹ (N-H), 1732 cm⁻¹ (C=O ester), 1658 cm⁻¹ (C=O amide), 746 cm⁻¹ (ArC-H OOP); **¹H NMR** (CDCl₃, 400 MHz) δ_{H} 1.25 (t, 3H, H-9, *J* 7.0 Hz), 3.00 (t, 2H, H-3, *J* 7.0 Hz), 3.25 (s, 2H, H-6), 3.63 (app. q, 2H, H-4, *J* 7.0 Hz), 4.14 (q, 2H, H-8, *J* 7.0 Hz), 7.01 (s, 1H, H-1), 7.09-7.17 (m, 2H, H-12, NH amide), 7.20 (t, 1H, H-13, *J* 7.5 Hz), 7.36 (d, 1H, H-14, *J* 7.5 Hz), 7.61 (d, 1H, H-11, *J* 7.5 Hz), 8.56 (br s, 1H, NH indole); **¹³C NMR** (CDCl₃, 100 MHz) δ_{C} 13.9 (C-9), 25.0 (C-3), 39.9 (C-4), 41.3 (C-6), 61.4 (C-8), 111.2 (C-14), 112.4 (C-2), 118.4 (C-11), 119.1 (C-12), 121.8 (C-13), 122.1 (C-1), 127.1 (C-10), 136.3 (C-15), 165.2 (C-5), 169.1 (C-7); **m/z** (ES⁺) 297 ([M+Na]⁺, 100%), **HRMS** (ES⁺) exact mass calculated for [M+Na]⁺ (C₁₅H₁₈N₂O₃Na⁺) requires **m/z** 297.1210, found **m/z** 297.1211.

Preparation and characterisation of ethyl 3-{[2-(5-bromo-1*H*-indol-3-yl)ethyl]amino}-3-oxopropanoate **14f**

Synthesised according to general procedure E on a 10 mmol scale of **13b** (2.4 g). Purified by column chromatography on silica gel eluting with petroleum ether/ethyl acetate 7:2 to 1:1 to give the title product as a pale yellow oil (2.03 g, 58%).




FT-IR $\nu_{\max}$ (NaCl) 3313 cm⁻¹ (br with shoulder, N-H), 1725 cm⁻¹ (C=O ester), 1653 cm⁻¹ (C=O amide), 750 cm⁻¹ (ArC-H OOP); **¹H NMR** (CDCl₃, 400 MHz) δ_{H} 1.25 (t, 3H, H-9, *J* 7.0 Hz), 2.94 (t, 2H, H-3, *J* 7.0 Hz), 3.28 (s, 2H, H-6), 3.59 (app. q, 2H, H-4, *J* 7.0 Hz), 4.15 (q, 2H, H-8, *J* 7.0 Hz), 7.03

(d, 1H, H-1, *J* 2.0 Hz), 7.18-7.28 (m, 3H, H-13, H-14, NH amide), 7.71 (d, 1H, H-11, *J* 1.5 Hz), 8.49 (br s, 1H, NH indole); ¹³C NMR (CDCl₃, 100 MHz) δ_C 14.0 (C-9), 24.9 (C-3), 39.9 (C-4), 41.1 (C-6), 61.5 (C-8), 112.5 & 112.6 (C-2 & C-12), 112.7 (Ar-CH), 121.2 (C-11), 123.3 (C-1), 124.8 (Ar-CH), 129.1 (C-10), 134.9 (C-15), 165.1 (C-5), 169.4 (C-7); *m/z* (ES⁻) 351, 353 ([M-H]⁻, 100%), HRMS (ES⁺) exact mass calculated for [M+Na]⁺ (C₁₅H₁₇N₂O₃BrNa⁺) requires *m/z* 375.0315 & 377.0295, found *m/z* 375.0316 & 377.0294.

Preparation and characterisation of ethyl 3-{[2-(7-methyl-1*H*-indol-3-yl)ethyl]amino}-3-oxopropanoate **14g**


Synthesised according to general procedure E on a 11.2 mmol scale of **13c** (1.95 g). Purified by column chromatography on silica gel eluting with petroleum ether/ethyl acetate 3:1 to 1:1 to give the title compound as an off-white solid (2.08 g, 64%).



m.p. 82-84 °C; **FT-IR** ν_{max}(NaCl) 3383 cm⁻¹ (N-H), 3306 cm⁻¹ (N-H), 1734 cm⁻¹ (C=O ester), 1658 cm⁻¹ (C=O amide), 750 cm⁻¹ (ArC-H OOP); ¹H NMR (CDCl₃, 400 MHz) δ_H 1.26 (t, 3H, H-9, *J* 7.0 Hz), 2.49 (s, 3H, H-15), 3.00 (t, 2H, H-3, *J* 7.0 Hz), 3.27 (s, 2H, H-6), 3.64 (app. q, 2H, H-4, *J* 6.5 Hz),

4.15 (q, 2H, H-8, *J* 7.0 Hz), 6.99-7.09 (m, 3H, H-1, H-12, Ar-H), 7.12 (br s, 1H, NH amide), 7.46 (d, 1H, Ar-H, *J* 8.0 Hz), 8.22 (br s, 1H, NH indole); ¹³C NMR (CDCl₃, 100 MHz) δ_C 13.9 (C-9), 16.5 (C-15), 25.2 (C-3), 39.9 (C-4), 41.3 (C-6), 62.4 (C-8), 113.2 (C-2), 116.3 (Ar-CH), 119.6 (Ar-CH), 120.4 (C-14), 121.8 (Ar-CH), 122.6 (Ar-CH), 126.8 (C-10), 135.9 (C-16), 165.0 (C-5), 169.3 (C-7); *m/z* (ES⁻) 287 ([M-H]⁻, 100%), HRMS (ES⁺) exact mass calculated for [M+Na]⁺ (C₁₆H₂₀N₂O₃Na⁺) requires *m/z* 311.1366, found *m/z* 311.1367.

2.2.2. General procedure F for the preparation of pro-nucleophiles **6**




Sodium hydride (1 equivalent) was suspended in tetrahydrofuran (5 mL per 1 mmol of dicarbonyl), and the suspension was cooled to 0 °C. Dicarbonyl **14** (1 equivalent) was added dropwise as a solution in tetrahydrofuran (2 mL per 1 mmol). The suspension was stirred for 1.5 hours at 0 °C (it became

clear meanwhile) and the relevant chloroformate (0.5 equivalents) was added in one portion to the vigorously stirred mixture. The resulting solution was stirred for 1 hour at 0 °C and further 30 minutes at room temperature. It was quenched with a saturated aqueous solution of ammonium chloride (3 mL per 1 mmol of substrate). The aqueous layer was diluted with water (3 mL per 1 mmol), and ethyl acetate was added (3 mL per 1 mmol). The layers were separated and the aqueous was re-extracted with ethyl acetate (2 × 3 mL per 1 mmol). The combined organics were dried over magnesium sulphate, filtered and concentrated under reduced pressure. The resulting oil was purified by column chromatography on silica gel eluting with petroleum ether / diethyl ether (see eluent conditions for each compound).

Preparation and characterisation of dimethyl {[2-(1*H*-indol-3-yl)ethyl]carbamoyl}malonate **6a**


Synthesised according to general procedure **F** on a 22.1 mmol scale of **14a** (5.75 g). The crude mixture was purified by column chromatography on silica gel eluting with petroleum ether/diethyl ether 1:4 to diethyl ether and then diethyl ether/ethyl acetate 9:1 to give the title product as an off-white solid (2.96 g, 84%).



m.p. 82-84 °C; **FT-IR** ν_{max} (NaCl) 3389 cm^{-1} (N-H), 3321 cm^{-1} (N-H), 1740 cm^{-1} (C=O ester), 1663 cm^{-1} (C=O amide), 747 cm^{-1} (ArC-H OOP); **¹H NMR** (CDCl₃, 400 MHz) δ_{H} 3.01 (t, 2H, H-3, *J* 7.0 Hz), 3.64 (app. q, 2H, H-4, *J* 7.0 Hz), 3.74 (s, 6H, H-8), 4.36 (s, 1H, H-6), 7.04 (d, 1H, H-1, *J* 2.5 Hz), 7.12 (ddd, 1H, H-11, *J* 8.0 Hz, 7.0 Hz, 1.0 Hz), 7.20 (ddd, 1H, H-12, *J* 8.0 Hz, 7.0 Hz, 1.0 Hz), 7.33-7.40 (m, 2H, H-13, NH amide), 7.61 (d, 1H, H-10, *J* 8.0 Hz), 8.44 (br s, 1H, NH indole); **¹³C NMR** (CDCl₃, 100 MHz) δ_{C} 24.8 (C-3), 40.2 (C-4), 53.3 (C-8), 58.6 (C-6), 111.2 (C-13), 112.2 (C-2), 118.5 (C-10), 119.2 (C-11), 121.9 (C-12), 122.3 (C-1), 127.1 (C-9), 136.3 (C-14), 161.9 (C-5), 165.9 (C-7); ***m/z*** (ES⁺) 341 ([M+Na]⁺, 80%), 659 ([2M+Na]⁺, 100%), **HRMS** (ES⁺) exact mass calculated for [M+Na]⁺ (C₁₆H₁₈N₂O₅Na⁺) requires *m/z* 341.1108, found *m/z* 341.1108.

Preparation and characterisation of dimethyl {[2-(5-bromo-1*H*-indol-3-yl)ethyl]carbamoyl}malonate **6b**


Synthesised according to general procedure **F** on a 2.16 mmol scale of **14b** (730 mg). The crude mixture was purified by chromatography on silica gel eluting with petroleum ether/diethyl ether 1:4 to diethyl ether to give the title compound as a pale yellow oil (280 mg, 65%).



FT-IR $\nu_{\max}$ (NaCl) 3374 cm^{-1} (N-H), 3308 cm^{-1} (N-H), 1739 cm^{-1} (C=O ester), 1662 cm^{-1} (C=O amide), 756 cm^{-1} (ArC-H OOP); **^1H NMR** (CDCl_3 , 400 MHz) δ_{H} 2.96 (t, 2H, H-3, J 7.0 Hz), 3.62 (app. q, 2H, H-4, J 7.0 Hz), 3.76 (s, 6H, H-8), 4.35 (s, 1H, H-6), 7.07 (d, 1H, H-1, J 1.0 Hz), 7.26 (d, 1H, H-13, J 8.5 Hz), 7.27 (dd, 1H, H-12, J 8.5 Hz, 1.5 Hz), 7.39 (br s, 1H, NH amide), 7.72 (d, 1H, H-10, J 1.5 Hz), 8.30 (br s, 1H, NH indole); **^{13}C NMR** (CDCl_3 , 100 MHz) δ_{C} 24.8 (C-3), 40.2 (C-4), 53.4 (C-8), 58.5 (C-6), 112.3 (C-2), 112.7 (2C, C-11, Ar-CH), 121.2 (C-10), 123.5 (C-1), 124.9 (Ar-CH), 129.1 (C-9), 134.9 (C-14), 161.9 (C-5), 166.0 (C-7); **m/z** (ES $^-$) 395, 397 ($[\text{M}-\text{H}]^-$, 90%), **HRMS** (ES $^+$) exact mass calculated for $[\text{M}+\text{Na}]^+$ ($\text{C}_{16}\text{H}_{17}\text{N}_2\text{O}_5\text{BrNa}^+$) requires **m/z** 419.0213 & 421.0193, found **m/z** 419.0211 & 421.0192.

Preparation and characterisation of dimethyl {[2-(7-methyl-1H-indol-3-yl)ethyl] carbamoyl}malonate 6c


Synthesised according to general procedure F on a 7.3 mmol scale of **14c** (2.00 g). The crude mixture was purified by chromatography on silica gel eluting with petroleum ether/diethyl ether 3:1 to 95:5 to give the title compound as a colourless crystalline solid (650 mg, 54% [92% brsm]).



m.p. 86-89 $^{\circ}\text{C}$; **FT-IR** $\nu_{\max}$ (NaCl) 3385 cm^{-1} (N-H), 3313 cm^{-1} (N-H), 1739 cm^{-1} (C=O ester), 1664 cm^{-1} (C=O amide), 751 cm^{-1} (ArC-H OOP); **^1H NMR** (CDCl_3 , 400 MHz) δ_{H} 2.49 (s, 3H, H-14), 3.02 (t, 2H, H-3, J 7.0 Hz), 3.65 (app. q, 2H, H-4, J 7.0 Hz), 3.76 (s, 6H, H-8), 4.35 (s, 1H, H-6), 7.00-7.10 (m, 3H, 3 $\times$ Ar-H), 7.31-7.38 (m, 1H, NH amide), 7.47 (d, 1H, Ar-H, J 7.5 Hz), 8.16 (br s, 1H, NH indole); **^{13}C NMR** (CDCl_3 , 100 MHz) δ_{C} 16.6 (C-14), 25.1 (C-3), 40.3 (C-4), 53.4 (C-8), 58.7 (C-6), 113.0 (C-2), 116.4 (Ar-CH), 119.7 (Ar-CH), 120.5 (C-13), 122.0 (C-1), 122.6 (C-11), 126.8 (C-9), 136.0 (C-15), 161.8 (C-5), 166.1 (C-7); **m/z** (ES $^-$) 331 ($[\text{M}-\text{H}]^-$, 100%), **HRMS** (ES $^+$) exact mass calculated for $[\text{M}+\text{Na}]^+$ ($\text{C}_{17}\text{H}_{20}\text{N}_2\text{O}_5\text{Na}^+$) requires **m/z** 355.1264, found **m/z** 355.1264.

Preparation and characterisation of dimethyl {[2-(7-ethyl-1*H*-indol-3-yl)ethyl]carbamoyl}malonate **6d**


Synthesised according to general procedure **F** on a 3.82 mmol scale of **14d** (1.1 g). The crude mixture was purified by chromatography on silica gel eluting with petroleum ether/diethyl ether 2:1 to 1:1 to give the title product as a pale yellow oil (0.44 g, 67% [91% brsm]).



FT-IR $\nu_{\max}$ (NaCl) 3384 cm^{-1} (N-H), 3324 cm^{-1} (N-H), 1740 cm^{-1} (C=O ester), 1663 cm^{-1} (C=O amide), 752 cm^{-1} (ArC-H OOP); **^1H NMR** (CDCl_3 , 400 MHz) δ_{H} 1.37 (t, 3H, H-15, J 7.5 Hz), 2.87 (q, 2H, H-14, J 7.5 Hz), 3.02 (t, 2H, H-3, J 7.0 Hz), 3.65 (app q, 2H, H-4, J 7.0 Hz), 3.75 (s, 6H, H-8), 4.36 (s, 1H, H-6), 7.03-7.13 (m, 3H, H-1, H-11, Ar-H), 7.34 (br s, 1H, NH amide), 7.48 (d, 1H, Ar-H, J 8.0 Hz), 8.17 (br s, 1H, NH indole); **^{13}C NMR** (CDCl_3 , 100 MHz) δ_{C} 13.8 (C-15), 23.9 (C-14), 25.0 (C-3), 40.2 (C-4), 53.3 (C-8), 58.7 (C-6), 113.0 (C-2), 116.3 (Ar-CH), 119.7 (Ar-CH), 120.6 (Ar-CH), 121.8 (Ar-CH), 126.6 (Ar-Cquat.), 126.9 (Ar-Cquat.), 135.2 (C-16), 161.8 (C-5), 166.0 (C-7); **m/z** (ES+) 369 ($[\text{M}+\text{Na}]^+$, 90%), **HRMS** (ES+) exact mass calculated for $[\text{M}+\text{Na}]^+$ ($\text{C}_{18}\text{H}_{22}\text{N}_2\text{O}_5\text{Na}^+$) requires m/z 369.1421, found m/z 369.1422.

Preparation and characterisation of diethyl {[2-(1*H*-indol-3-yl)ethyl]carbamoyl}malonate **6e**

Synthesised according to general procedure **F** on a 10 mmol scale of **14e** (2.74 g). The crude mixture was purified by column chromatography on silica gel eluting with petroleum ether/ethyl acetate 5:1 to 3:2 to give the title compound as a pale yellow oil (860 mg, 50%).




FT-IR $\nu_{\max}$ (NaCl) 3384 cm^{-1} (N-H), 3314 cm^{-1} (N-H), 1734 cm^{-1} (C=O ester), 1662 cm^{-1} (C=O amide), 746 cm^{-1} (ArC-H OOP); **^1H NMR** (CDCl_3 , 400 MHz) δ_{H} 1.26 (t, 6H, H-9, J 7.0 Hz), 3.02 (t, 2H, H-3, J 7.0 Hz), 3.65 (app. q, 2H, H-4, J 7.0 Hz), 4.22 (q, 4H, H-8, J 7.0 Hz), 4.32 (s, 1H, H-6), 7.06 (s, 1H, H-1), 7.13 (ddd, 1H, H-12, J 8.0 Hz, 7.0 Hz, 1.0 Hz), 7.20 (ddd, 1H, H-13, J 8.0 Hz, 7.0 Hz, 1.0 Hz), 7.35-7.43 (m, 2H, H-14, NH amide), 7.62 (d, 1H, H-11, J 8.0 Hz), 8.28 (br s, 1H, NH indole); **^{13}C NMR** (CDCl_3 , 100 MHz) δ_{C} 13.8 (C-9), 24.9 (C-3), 40.2 (C-4), 59.1 (C-6), 62.5 (C-8), 111.2 (C-14), 112.5 (C-2), 118.6 (C-11), 119.3 (C-12), 122.0 (C-13), 122.2 (C-1), 127.2 (C-10), 136.3 (C-15), 162.1

(C-5), 165.6 (C-7); **m/z** (ES⁻) 345 ([M-H]⁻, 100%), **HRMS** (ES⁺) exact mass calculated for [M+Na]⁺ (C₁₈H₂₂N₂O₅Na⁺) requires **m/z** 369.1421, found **m/z** 369.1421.

Preparation and characterisation of diethyl {[2-(5-bromo-1*H*-indol-3-yl)ethyl]carbamoyl}malonate **6f**

Synthesised according to general procedure **F** on a 5.7 mmol scale of **14f** (2.0 g). The crude mixture was purified by column chromatography on silica gel eluting with petroleum ether/diethyl ether 1:4 to diethyl ether to give the title product as a pale yellow oil (510 mg, 42%).




FT-IR $\nu_{\max}$ (NaCl) 3372 cm⁻¹ (N-H), 3311 cm⁻¹ (N-H), 1733 cm⁻¹ (C=O ester), 1661 cm⁻¹ (C=O amide), 755 cm⁻¹ (ArC-H OOP); **¹H NMR** (CDCl₃, 400 MHz) δ_{H} 1.26 (t, 6H, H-9, *J* 7.0 Hz), 2.95 (t, 2H, H-3, *J* 7.0 Hz), 3.61 (app. q, 2H, H-4, *J* 7.0 Hz), 4.21 (q, 4H, H-8, *J* 7.0 Hz), 4.31 (s, 1H, H-6), 7.06

(d, 1H, H-1, *J* 2.0 Hz), 7.23 (d, 1H, H-14, *J* 8.5 Hz), 7.25 (dd, 1H, H-13, *J* 8.5 Hz, 1.5 Hz), 7.44 (br s, 1H, NH amide), 7.71 (d, 1H, H-11, *J* 1.5 Hz), 8.43 (br s, 1H, NH indole); **¹³C NMR** (CDCl₃, 100 MHz) δ_{C} 13.8 (C-9), 24.8 (C-3), 40.2 (C-4), 59.0 (C-6), 62.6 (C-8), 112.2 & 112.6 (C-2 & C-12), 112.7 (Ar-CH), 121.2 (C-11), 123.5 (C-1), 124.8 (Ar-CH), 129.0 (C-10), 134.9 (C-15), 162.2 (C-5), 165.6 (C-7); **m/z** (ES⁻) 423, 425 ([M-H]⁻, 55%), 847, 849, 851 ([2M-H]⁻, 50%, 100%, 50%), **HRMS** (ES⁺) exact mass calculated for [M+Na]⁺ (C₁₈H₂₁N₂O₅BrNa⁺) requires **m/z** 447.0526 & 449.0506, found **m/z** 447.0524 & 449.0504.

Preparation and characterisation of diethyl {[2-(7-methyl-1*H*-indol-3-yl)ethyl]carbamoyl}malonate **6g**


Synthesised according to general procedure **F** on a 7.2 mmol scale of **14g** (2.08 g). The crude mixture was purified by column chromatography on silica gel eluting with petroleum ether/diethyl ether 1:4 to diethyl ether and then diethyl ether/ethyl acetate 4:1 to give the title compound as an off-white solid (1.0 g, 77%).




m.p. 83-87 °C; **FT-IR** $\nu_{\max}$ (NaCl) 3384 cm⁻¹ (N-H), 3319 cm⁻¹ (N-H), 1733 cm⁻¹ (C=O ester), 1662 cm⁻¹ (C=O amide); **¹H NMR** (CDCl₃, 400 MHz) δ_{H} 1.27 (t, 6H, H-9, *J* 7.0 Hz), 2.49 (s, 3H, H-15), 3.02 (t, 2H, H-3, *J* 7.0 Hz), 3.65 (app. q,

2H, H-4, *J* 7.0 Hz), 4.22 (q, 4H, H-8, *J* 7.0 Hz), 4.32 (s, 1H, H-6), 6.99-7.10 (m, 3H, 3 × Ar-H), 7.35-7.42 (m, 1H, NH amide), 7.48 (d, 1H, Ar-H, *J* 8.0 Hz), 8.17 (br s, 1H, NH indole); ¹³C NMR (CDCl₃, 100 MHz) δ_C 13.9 (C-9), 16.6 (C-15), 25.2 (C-3), 40.2 (C-4), 59.1 (C-6), 62.6 (C-8), 113.1 (C-2), 116.4 (Ar-CH), 119.6 (Ar-CH), 120.4 (C-14), 122.0 (C-1), 122.6 (C-12), 126.8 (C-10), 136.0 (C-16), 162.1 (C-5), 165.7 (C-7); *m/z* (ES⁻) 359 ([M-H]⁻, 100%), HRMS (ES⁺) exact mass calculated for [M+Na]⁺ (C₁₉H₂₄N₂O₅Na⁺) requires *m/z* 383.1577, found *m/z* 383.1576.

2.3. Preparation and characterisation of dimethyl {[2-(1H-indol-3-yl)ethyl]carbamoyl}(3-oxobutyl)malonate **8a** (substrate for optimisation)




Pro-nucleophile **6a** (420 mg, 1.32 mmol, 1 equivalent) was dissolved in dichloromethane (5 mL) and stirred vigorously at room temperature. Liquid BEMP (45 μL, 0.16 mmol, 0.1 equivalents) was added to the solution immediately followed by the addition of MVK **7a** (0.41 mL, 4.90 mmol, 3 equivalents). The mixture was left stirring at room temperature for 16 hours (completion confirmed by TLC and LC-MS). The solvent was removed *in vacuo* and the residue purified by column chromatography on silica gel eluting with petroleum ether/diethyl ether 4:1 to 1:2 to afford the title product as a colourless gum (420 mg, 82%).



FT-IR ν_{max}(NaCl) 3386 cm⁻¹ (N-H), 3352 cm⁻¹ (N-H), 1731 cm⁻¹ (C=O ester), 1659 cm⁻¹ (C=O amide), 749 cm⁻¹ (ArC-H OOP); ¹H NMR (CDCl₃, 400 MHz) δ_H 1.99 (s, 3H, H-10), 2.39 (t, 2H, H-7, *J* 7.5 Hz), 3.49 (t, 2H, H-8, *J* 7.5 Hz), 3.06 (t, 2H, H-3, *J* 7.0 Hz), 3.68-3.77 (m, 8H, H-4, 2 × CO₂CH₃), 7.09 (s, 1H, H-1), 7.14

(t, 1H, H-13, *J* 7.5 Hz), 7.21 (t, 1H, H-14, *J* 7.5 Hz), 7.39 (d, 1H, H-15, *J* 8.0 Hz), 7.65 (d, 1H, H-12, *J* 8.0 Hz), 8.16 (t, 1H, NH amide), 8.88 (br s, 1H, NH indole); ¹³C NMR (CDCl₃, 100 MHz) δ_C 24.7 (C-3), 28.1 (C-8), 29.4 (C-10), 38.2 (C-7), 39.8 (C-4), 53.0 (2 × CO₂CH₃), 62.8 (C-6), 111.1 (C-15), 111.8 (C-2), 118.3 (C-12), 118.9 (C-13), 121.6 (C-14), 122.2 (C-1), 127.0 (C-11), 136.2 (C-16), 165.6 (C-5), 168.9 (2 × CO₂CH₃), 206.7 (C-9); *m/z* (ES⁻) 387 ([M-H]⁻, 100%), HRMS (ES⁺) exact mass calculated for [M+Na]⁺ (C₂₀H₂₄N₂O₆Na⁺) requires *m/z* 411.1527, found *m/z* 411.1527.

3. Proof of principle for the site-isolated PS-BEMP and bulky BPA catalysed Michael addition/enantioselective *N*-acyliminium cyclisation cascade



General procedure

tert-Butylbenzene (9.3 mg, 0.0694 mmol) was dissolved in 2.00 mL of CD₂Cl₂. 0.2 mL of this solution (0.0069 mmol, 0.069 eq.) were added to a solution of **6a** (31.8 mg, 0.1 mmol, 1 eq.) and (*R*)-**3** (5 mol %: 4.3 mg, 0.005 mmol; 10 mol %: 8.6 mg, 0.01 mmol; 20 mol % 17.3 mg, 0.02 mmol) in CD₂Cl₂ (0.5 mL) in an NMR tube at room temperature. PS-BEMP (4.5 mg, 0.01 mmol, 10 mol %) was added, immediately followed by the addition of MVK (27 μ L, 0.3 mmol, 3 eq.) in one portion. The resulting mixture was stirred (600 rpm) at room temperature and the conversion of **6a** into **8a/9a** was monitored by NMR analysis. After full conversion of **6a**, the crude mixture was purified by column chromatography on silica gel eluting with petroleum ether/diethyl ether 1:4 to diethyl ether.

Table 1. Proof of principle for the site-isolated base and acid catalysed tandem Michael addition / enantioselective *N*-acyliminium cyclisation

Entry	Base (10 mol %)	Acid ^[a]	Time	Yield of 8a (%)	Observation
1	PS-piperidine	—	24 h	N.R.	-
2	PS-BEMP	—	6 h	93	-
3	Liq. BEMP	—	2 h	89	-
4	—	DPP	24 h	N.R.	-
5	—	TPS-BPA	24 h	N.R.	-
6	Liq. BEMP	DPP	24 h	N.R.	-
7	Liq. BEMP	TPS-BPA	24 h	N.R.	-
8	PS-BEMP	DPP	24 h	N.R.	-
9	PS-BEMP	TPS-BPA ^[b]	13 h	91	< 1% of 9a
10	PS-BEMP	TPS-BPA	57 h	88	3% of 9a
11	PS-BEMP	TPS-BPA ^[c]	57 h	37 (79.5% conv. 6a)	8a/9a ~ 2:1

^[a] 10 mol % unless otherwise stated; ^[b] 5 mol %; ^[c] 20 mol %; N.R. = no reaction.

4. Titration experiments

Procedure for the titration of DPP


tert-Butylbenzene (3.1 mg, 0.0231 mmol) was dissolved in 5.00 mL of CD₂Cl₂. 0.2 mL of this solution were added to a solution of DPP (12.5 mg, 0.05 mmol in 0.5 mL of CD₂Cl₂) in an NMR tube

at room temperature, immediately followed by the addition of PS-BEMP (22.7 mg, 0.05 mmol) in one portion. The resulting mixture was stirred (600 rpm) at room temperature and the amount of acid in solution was monitored by NMR analysis and measured accurately against the internal standard (*tert*-butylbenzene).

Procedure for the titration of TPS BPA (R)-3

tert-Butylbenzene (2.1 mg) was dissolved in 5.00 mL of CD₂Cl₂. 0.5 mL of this solution were added to a solution of (R)-3 (21.6 mg, 0.025 mmol in 0.2 mL of CD₂Cl₂) in an NMR tube at room temperature, immediately followed by the addition of PS-BEMP (0.5 eq.: 5.7 mg; 1 eq.: 11.4 mg; 2 eq.: 22.7 mg; 3 eq.: 34.1 mg) in one portion. The resulting mixture was stirred (600 rpm) at room temperature and the amount of acid was monitored by NMR analysis and measured against the internal standard (*tert*-butylbenzene).

Plots of the amount of acid in solution



Graph 1: Titration of TPS BPA (R)-3 in the presence of PS-BEMP

Red crosses × : 0.5 eq. of PS-BEMP; **Magenta crosses +** : 1 eq. of PS-BEMP; **Blue triangles Δ** : 2 eq. of PS-BEMP; **Orange squares □** : 3 eq. of PS-BEMP.

5. NMR conversions of **6^a** into **8^a** in the presence of 10 mol % of PS-BEMP and varying amounts of acid **3**

General procedures for the NMR experiments


Experiment with 10 mol % of PS-BEMP and no acid

tert-Butylbenzene (5.6 mg) was dissolved in 2.00 mL of CD₂Cl₂. 0.6 mL of the above CD₂Cl₂ solution were added to a solution of **6a** (31.8 mg, 0.1 mmol, in 0.1 mL of CD₂Cl₂) in an NMR tube at room temperature. PS-BEMP (4.5 mg, 0.01 mmol) was added, immediately followed by the addition of MVK (27 µL, 0.3 mmol) in one portion. The resulting mixture was stirred (600 rpm) at room temperature and the conversion of **6a** into **8a** was monitored by NMR analysis and measured against the internal standard (*tert*-butylbenzene).


Experiment with 10 mol % of PS-BEMP and 5 to 20 mol % of acid (*R*)-**3**

tert-Butylbenzene (9.3 mg, 0.0694 mmol) was dissolved in 2.00 mL of CD₂Cl₂. 0.2 mL of the above CD₂Cl₂ solution were added to a solution of **6a** (31.8 mg, 0.1 mmol in 0.5 mL of CD₂Cl₂) and (*R*)-**3** (5 mol %: 4.3 mg, 0.005 mmol; 10 mol %: 8.6 mg, 0.01 mmol; 20 mol % 17.3 mg, 0.02 mmol) in an NMR tube at room temperature. PS-BEMP (4.5 mg, 0.01 mmol) was added, immediately followed by the addition of MVK (27 µL, 0.3 mmol) in one portion. The resulting mixture was stirred (600 rpm) at room temperature and the conversion of **6a** into **8a** was monitored by NMR analysis and measured against the internal standard (*tert*-butylbenzene).

Plots of the conversion of 6a into 8a in the presence of 10 mol % of PS-BEMP and varying amounts of (R)-3




Graph 2: ^1H NMR Conversion of 6a - **Green diamonds ♦** : no acid; **Magenta squares ■** : 5 mol % of (R)-3; **Red triangles ▲** : 10 mol % of (R)-3; **Blue circles ●** : 20 mol % of (R)-3;




Graph 3: Formation of 8a measured by ^1H NMR - **Green diamonds ♦** : no acid; **Magenta squares ■** : 5 mol % of (R)-3; **Red triangles ▲** : 10 mol % of (R)-3; **Blue circles ●** : 20 mol % of (R)-3;

Superimposed disappearance of 6a / Formation of 8a



Graph 4: Conversion of 6a into 8a measured by ^1H NMR - Filled markers (solid curves): amount of 6a; Hollow markers (dashed curves): amount of 8a; **Green diamonds ♦** : no acid; **Magenta squares ■** : 5 mol % of (R)-3; **Red triangles ▲** : 10 mol % of (R)-3; **Blue circles ●** : 20 mol % of (R)-3;

6. Optimisation of the enantioselective *N*-acyliminium cyclisation



Procedure for the *N*-acyliminium cyclisation of 7a

8a (19.4 mg, 0.05 mmol, 1 equivalent) was dissolved in toluene (7 mL). The stirred mixture was heated to reflux and the catalyst (R)-3, (R)-4 or (R)-15 was added (0.01 mmol, 0.1 equivalents). The mixture was heated at reflux for 16-48 hours (completion monitored by TLC and LC-MS (ES⁺)). The

solvent was removed, the residue redissolved in the minimum amount of dichloromethane and the product purified by column chromatography on silica gel eluting with petroleum ether/ethyl acetate 3:1 to 1:1. The enantiomeric excess of the combined collected fractions was measured.

Table 2: Optimisation of the enantioselective *N*-acyliminium cyclisation

Entry	[7a] _i (mM)	Acid	R / Y	Time	Yield (%)	e.e. (%)
1	7 mM	(<i>R</i>)- 3	SiPh ₃ / OH	12 h	99	52
2	7 mM	(<i>R</i>)- 4	[H ₈] SiPh ₃ / OH	24 h	99	60
3	7 mM	(<i>R</i>)- 15a	SiEt ₃ / OH	65 h	76	35
4	7 mM	(<i>R</i>)- 15b	Si(^{<i>i</i>} Pr) ₃ / OH	18 h	87	49
5	7 mM	(<i>R</i>)- 15c	SiPh ₂ ^{<i>t</i>} Bu / OH	48 h	81	38
6	7 mM	(<i>R</i>)- 15d	SiMe ₂ ^{<i>t</i>} Bu / OH	12 h	99	16
7	7 mM	(<i>R</i>)- 15e	Si(<i>m</i> -xylyl) ₃ / OH	48 h	99	27
8	7 mM	(<i>R</i>)- 15f	3,5-(CF ₃) ₂ Ph / OH	12 h	95	52
9	7 mM	(<i>R</i>)- 15g	2,4,6-(^{<i>i</i>} Pr) ₃ Ph / OH	16 h	92	58
10	7 mM	(<i>R</i>)- 15h	[H ₈] 2,4,6-(^{<i>i</i>} Pr) ₃ Ph / OH	30 h	49	65
11	7 mM	(<i>R</i>)- 15i	9-anthryl / OH	16 h	98	29
12	7 mM	(<i>R</i>)- 15j	9-phenanthryl / OH	16 h	92	26
13	7 mM	(<i>R</i>)- 15k	SiPh ₃ / NHTf	16 h	99	45
14	5 mM	(<i>R</i>)- 4	[H ₈] SiPh ₃ / OH	20 h	99	55
15	10 mM	(<i>R</i>)- 4	[H ₈] SiPh ₃ / OH	8 h	99	55
16	17 mM	(<i>R</i>)- 4	[H ₈] SiPh ₃ / OH	7 h	99	50

(*R*)-**3** and (*R*)-**15f** (3,5-(CF₃)₂Ph BPA) induced similar levels of enantioselectivity (52% e.e., entries 1 and 8). Interestingly, (*R*)-**15g** (TRIP BPA) slightly improved the enantioselectivity to 58% e.e. (entry 9). When H₈-BINOL derivative (*R*)-**4** was evaluated in the cyclisation, it enhanced the selectivity to 60% e.e. (entry 2). The H₈-BINOL-derived analogue (*R*)-**15h** of BPA (*R*)-**15g** was assessed and as expected it improved on the selectivity observed for the binaphthyl derivative (65% e.e. vs. 58% e.e., entries 10 and 9 respectively). The influence of the concentration was also studied and as observed in our previous studies, the optimal concentration was found to be 7 mM (60% e.e. with (*R*)-**4**, entry 2) and the selectivities were diminished at higher or lower dilution (entries 14-16).^[5,8]


7. Optimisation of the base and acid catalysed tandem Michael addition / enantioselective *N*-acyliminium cyclisation of **6a** into **9a**

General procedure

6a (31.8 mg, 0.1 mmol, 1 equivalent), PS-BEMP **1a** (4.5 mg, 0.01 mmol, 0.1 eq.) and catalyst (*R*)-**3**, (*R*)-**4** or (*R*)-**15** (0.2 eq.) were placed in a dry RB-flask and toluene (14 mL) was added. The mixture

was stirred at r.t. and MVK **7a** (0.15-0.3 mmol, 1.5 to 3 eq.) was added. The mixture was stirred at room temperature (time indicated in Table 3). It was then heated at reflux (time indicated in Table 3). The solvent was removed, the residue redissolved in the minimum amount of dichloromethane and the product purified by column chromatography on silica gel eluting with petroleum ether/ethyl acetate 3:1 to 1:1.

Table 3: Optimisation of the base and acid catalysed tandem Michael addition / enantioselective *N*-acyliminium cyclisation of **6a into (+)-**9a****




Entry	MVK	Acid	R / Y	Time (r.t.)	Time (reflux)	Yield	e.e.
1	1.5 eq.	(<i>R</i>)- 3	SiPh ₃ / OH	16 h	36 h	25%	51%
2	2 eq.	(<i>R</i>)- 3	SiPh ₃ / OH	48 h	12 h	90%	43%
3	3 eq.	(<i>R</i>)- 3	SiPh ₃ / OH	17 h	20 h	78%	49%
4	3 eq.	(<i>R</i>)- 15h	[H ₈] 2,4,6-(iPr) ₃ Ph / OH	20 h	48 h	N. O.	-
5	3 eq.	(<i>R</i>)- 4	[H ₈] SiPh ₃ / OH	24 h	24 h	81%	57%

N.O. = Not observed.

Our initial attempt to perform a one-pot cascade using 1.5 eq. of MVK resulted in the isolation of a moderate yield of desired product with a pleasing 51% ee (25% yield, entry 1). To improve the reactivity (the rate of the Michael addition), larger amounts of MVK were used and with 3 equivalents of the Michael acceptor, the reaction proceeded in high yield and good enantioselectivity (entry 3). When **6a** was treated with the previously identified optimal catalyst and under the optimal conditions found for the cascade, we observed that (*R*)-**15h** failed to provide the desired reactivity, however (*R*)-**4** participated in the dual catalysis to yield (+)-**9a** in a pleasing 81% yield and an improved 57% ee (entry 5). The latter conditions were used to probe the scope of the cascade.

8. General procedure G for the base-catalysed Michael addition / acid-catalysed enantioselective *N*-acyliminium cyclisation cascade




Pro-nucleophile **6** (0.2 mmol, 1 equivalent), PS-BEMP **1a** (0.02 mmol, 0.1 equivalents, 9.0 mg) and catalyst (*R*)-**4** (0.04 mmol, 0.2 equivalents, 34.9 mg) were placed in a dry flask and dry toluene (28 mL) was added immediately followed by the addition of vinyl ketone **7** (0.6 mmol, 3 equivalents) in one portion. The resulting suspension was stirred at room temperature until full conversion to the Michael adduct (**8**) (LC-MS (ES⁺) monitoring). The mixture was then heated at reflux until full conversion to the tetracycle **9** (monitoring by LC-MS and TLC). The solvent was removed *in vacuo* and the residue purified by column chromatography on silica gel.

Note: All racemates were prepared in a one pot procedure using BEMP (0.1 equivalents) followed by addition of *para*-toluenesulphonic acid (0.2 equivalents) when the Michael addition was complete.

Preparation and characterisation of dimethyl (12*bR*)-12*b*-methyl-4-oxo-1,2,6,7,12,12*b*-hexahydroindolo[2,3-*a*]quinolizine-3,3(4*H*)-dicarboxylate (+)-**9a**

Prepared according to general procedure **G**. Stirred at room temperature for 17 hours then heated at reflux in toluene for 36 hours. The crude mixture was purified by column chromatography on silica gel eluting with petroleum ether/ethyl acetate 3:1 to 1:1 to afford the title product as an off-white solid (56 mg, 76%).

56% e.e. (Chiralcel OD, 85:15 hexane/isopropanol, 1 ml/min, 220 nm, major *t_R* = 16.7 min, minor *t_R* = 13.7 min); [α]_D²⁵ = + 53.0 (*c* 1.0, CHCl₃).




m.p. 232-237 °C; **FT-IR** ν_{max} (NaCl) 3305 cm⁻¹ (N-H), 1748 cm⁻¹ (C=O ester), 1735 cm⁻¹ (C=O ester), 1628 cm⁻¹ (C=O amide), 749 cm⁻¹ (ArC-H OOP); ¹H NMR (CDCl₃, 400 MHz) δ_{H} 1.73 (s, 3H, H-10), 2.00 (ddd, 1H, H-8a, *J* 14.0 Hz, 12.0 Hz, 3.0 Hz), 2.20 (ddd, 1H, H-8b, *J* 14.0 Hz, 6.0 Hz, 3.0 Hz), 2.55 (ddd, 1H, H-7a, *J* 14.0 Hz, 6.0 Hz, 3.5 Hz), 2.65 (ddd, 1H, H-7b, *J* 13.5 Hz, 12.0 Hz, 3.0 Hz), 2.76 (ddd, 1H, H-3a, *J*

15.5 Hz, 4.5 Hz, 1.5 Hz), 2.87 (ddd, 1H, H-3b, J 15.5 Hz, 11.5 Hz, 5.5 Hz), 3.12 (ddd, 1H, H-4a, J 12.5 Hz, 11.5 Hz, 4.5 Hz), 3.74 (s, 3H, CO₂CH₃), 3.84 (s, 3H, CO₂CH₃), 5.09 (ddd, 1H, H-4b, J 12.5 Hz, 5.0 Hz, 1.0 Hz), 7.14 (app. td, 1H, H-13, J 7.5 Hz, 1.0 Hz), 7.21 (app. td, 1H, H-14, J 7.5 Hz, 1.5 Hz), 7.35 (d, 1H, H-15, J 8.0 Hz), 7.51 (d, 1H, H-12, J 7.5 Hz), 7.79 (br s, 1H, NH); ¹³C NMR (CDCl₃:d₄-MeOD 19:1, 100 MHz) δ_C 21.0 (C-3), 25.0 (C-8), 26.5 (C-10), 31.7 (C-7), 37.6 (C-4), 53.2 (CO₂CH₃), 53.3 (CO₂CH₃), 57.7 (C-9), 63.5 (C-6), 107.4 (C-2), 111.0 (C-15), 118.1 (C-12), 119.2 (C-13), 121.7 (C-14), 126.3 (C-11), 136.3 (C-1), 137.4 (C-16), 163.4 (C-5), 168.4 (CO₂Me), 168.7 (CO₂Me); m/z (ES⁻) 369 ([M-H]⁻, 80%), HRMS (ES⁺) exact mass calculated for [M+Na]⁺ (C₂₀H₂₂N₂O₅Na⁺) requires m/z 393.1421, found m/z 393.1420.

Preparation and characterisation of dimethyl (12bR)-9-bromo-12b-methyl-4-oxo-1,2,6,7,12,12b-hexahydroindolo[2,3-a]quinolizine-3,3(4H)-dicarboxylate (+)-9b

Prepared according to general procedure G. Stirred at room temperature for 48 hours then heated at reflux in toluene for 72 hours. The crude mixture was purified by column chromatography on silica gel eluting with petroleum ether/ethyl acetate 3:1 to 1:1 to afford the title product as an off-white solid (71 mg, 79%).

77% e.e. (Chiralcel AD, 80:20 hexane/isopropanol, 1 ml/min, 220 nm, major t_R = 14.1 min, minor t_R = 43.8 min); $[\alpha]_D^{25}$ = +41.1 (c 1.20, CHCl₃).




m.p. 241-247 °C (dec.); **FT-IR** ν_{max} (NaCl) 3291 cm⁻¹ (N-H), 1748 cm⁻¹ (C=O ester), 1735 cm⁻¹ (C=O ester), 1628 cm⁻¹ (C=O amide), 756 cm⁻¹ (ArC-H OOP); ¹H NMR (CDCl₃, 400 MHz) δ_H 1.69 (s, 3H, H-10), 1.96 (ddd, 1H, H-8a, J 14.5 Hz, 12.5 Hz, 3.0 Hz), 2.25 (ddd, 1H, H-8b, J 14.0 Hz, 6.0 Hz, 3.0 Hz), 2.49 (ddd, 1H, H-7a, J 14.0 Hz, 6.0 Hz, 3.5 Hz), 2.60 (app. td, 1H, H-7b, J 13.0 Hz, 3.0 Hz), 2.68 (dd, 1H, H-3a, J 15.5 Hz, 3.5 Hz), 2.79 (ddd, 1H, H-3b, J 17.0 Hz, 11.5 Hz, 5.0 Hz), 3.08 (app. td, 1H, H-4a, J 12.5 Hz, 4.0 Hz), 3.70 (s, 3H, CO₂CH₃), 3.80 (s, 3H, CO₂CH₃), 5.02 (dd, 1H, H-4b, J 13.0 Hz, 4.5 Hz), 7.17 (d, 1H, H-15, J 8.5 Hz), 7.21 (dd, 1H, H-14, J 8.5 Hz, 1.5 Hz), 7.57 (d, 1H, H-12, J 1.5 Hz), 9.28 (br s, 1H, NH); ¹³C NMR (CDCl₃, 100 MHz) δ_C 20.9 (C-3), 25.9 (C-7), 26.7 (C-10), 31.8 (C-8), 37.5 (C-4), 53.3 (CO₂CH₃), 53.3 (CO₂CH₃), 57.5 (C-9), 63.5 (C-6), 107.5 (C-2), 112.5 (C-15), 112.6 (C-13), 120.9 (C-12), 124.6 (C-14), 128.2 (C-11), 134.8 (C-16), 138.6 (C-1), 163.3 (C-5), 168.4 (CO₂Me), 168.6 (CO₂Me); m/z (ES⁺) 471, 473 ([M+Na]⁺, 100%), HRMS (ES⁺)

exact mass calculated for $[M+H]^+$ ($C_{20}H_{22}N_2O_5Br^+$) requires m/z 449.0707 & 451.0687, found m/z 449.0703 & 451.0686.

Preparation and characterisation of dimethyl (12b*R*)-11,12b-dimethyl-4-oxo-1,2,6,7,12,12b-hexahydroindolo[2,3-*a*]quinolizine-3,3(4*H*)-dicarboxylate (+)-9c

Prepared according to general procedure G. Stirred at room temperature for 12 hours then heated at reflux in toluene for 72 hours. The crude mixture was purified by column chromatography on silica gel eluting with petroleum ether/ethyl acetate 4:1 to 3:2 to afford the title product as an off-white solid (69 mg, 90%).

66% e.e. (Chiralcel OD, 90:10 hexane/isopropanol, 1 ml/min, 220 nm, major t_R = 31.6 min, minor t_R = 25.6 min); $[\alpha]_D^{25} = +56.5$ (c 1.15, $CHCl_3$).



m.p. 216-223 °C; **FT-IR** ν_{max} (NaCl) 3321 cm^{-1} (N-H), 1736 cm^{-1} (2 signals with a shoulder, $2 \times C=O$ ester), 1629 cm^{-1} ($C=O$ amide), 750 cm^{-1} (ArC-H OOP); **1H NMR** ($CDCl_3:d_4$ -MeOD 9:1, 500 MHz) δ_H 1.77 (s, 3H, H-10), 2.02-2.11 (m, 1H, H-7a), 2.31-2.40 (m, 1H, H-7b), 2.50 (s, 3H, H-16), 2.56 (ddd, 1H, H-8a, J 13.5 Hz, 9.0 Hz, 3.0 Hz), 2.67 (app. td, 1H, H-8b, J 13.0 Hz, 2.5


Hz), 2.77 (dd, 1H, H-3a, J 16.0 Hz, 4.0 Hz), 2.89 (ddd, 1H, H-3b, J 16.0 Hz, 12.5 Hz, 5.5 Hz), 3.16 (app. td, 1H, H-4a, J 12.5 Hz, 4.0 Hz), 3.74 (s, 3H, CO_2CH_3), 3.83 (s, 3H, CO_2CH_3), 5.10 (dd, 1H, H-4b, J 12.5 Hz, 5.5 Hz), 7.02 (d, 1H, H-14, J 7.0 Hz), 7.08 (app. t, 1H, H-13, J 7.5 Hz), 7.37 (d, 1H, H-12, J 7.5 Hz), 8.39 (br s, 1H, NH); **^{13}C NMR** ($CDCl_3:d_4$ -MeOD 9:1, 125 MHz) δ_C 16.6 (C-16), 21.2 (C-3), 25.2 (C-8), 26.9 (C-10), 31.9 (C-7), 37.5 (C-4), 53.2 (CO_2CH_3), 53.3 (CO_2CH_3), 57.6 (C-9), 63.5 (C-6), 108.7 (C-2), 115.9 (C-12), 119.9 (C-13), 120.4 (C-15), 122.8 (C-14), 126.1 (C-11), 135.6 (C-17), 137.0 (C-1), 163.2 (C-5), 168.4 (CO_2Me), 168.6 (CO_2Me); **m/z** (ES+) 407 ($[M+Na]^+$, 100%), **HRMS** (ES+) exact mass calculated for $[M+Na]^+$ ($C_{21}H_{24}N_2O_5Na^+$) requires m/z 407.1577, found m/z 407.1577.

Preparation and characterisation of dimethyl (12b*R*)-11-ethyl-12b-methyl-4-oxo-1,2,6,7,12,12b-hexahydroindolo[2,3*a*]quinolizine-3,3(4*H*)-dicarboxylate (+)-9d

Prepared according to general procedure G. Stirred at room temperature for 24 hours then heated at reflux in toluene for 72 hours. The crude mixture was purified by column chromatography on silica

gel eluting with petroleum ether/ethyl acetate 4:1 to 3:2 to afford the title product as a pale yellow gum (50 mg, 63%).

68% e.e. (Chiralcel OD, 90:10 hexane/isopropanol, 1 ml/min, 220 nm, major t_R = 23.1 min, minor t_R = 18.7 min); $[\alpha]_D^{25} = +78.3$ (c 1.50, CHCl_3).




FT-IR ν_{max} (NaCl) 3325 cm^{-1} (N-H), 1749 cm^{-1} (C=O ester), 1736 cm^{-1} (C=O ester), 1630 cm^{-1} (C=O amide), 752 cm^{-1} (ArC-H OOP); **^1H NMR** (CDCl_3 , 400 MHz) δ_{H} 1.37 (t, 3H, H-17, J 7.5 Hz), 1.75 (s, 3H, H-10), 2.02 (app. td, 1H, H-8a, J 14.0 Hz, 3.0 Hz), 2.30 (ddd, 1H, H-8b, J 14.0 Hz, 6.0 Hz, 3.0 Hz), 2.56 (ddd,

1H, H-7a, J 14.0 Hz, 6.0 Hz, 3.5 Hz), 2.66 (ddd, 1H, H-7b, J 13.5 Hz, 12.5 Hz, 3.0 Hz), 2.76 (dd, 1H, H-3a, J 15.5 Hz, 3.5 Hz), 2.82-2.92 (m, 3H, H-3b, H-16), 3.13 (app. td, 1H, H-4a, J 12.5 Hz, 4.5 Hz), 3.74 (s, 3H, CO_2CH_3), 3.84 (s, 3H, CO_2CH_3), 5.09 (dd, 1H, H-4b, J 13.0 Hz, 4.5 Hz), 7.06 (d, 1H, H-12, J 7.5 Hz), 7.11 (t, 1H, H-13, J 7.5 Hz), 7.37 (d, 1H, H-14, J 7.5 Hz), 8.01 (br s, 1H, NH); **^{13}C NMR** (CDCl_3 , 100 MHz) δ_{C} 13.8 (C-17), 21.3 (C-3), 23.9 (C-16), 25.2 (C-7), 27.0 (C-10), 32.2 (C-8), 37.6 (C-4), 53.4 (CO_2CH_3), 53.5 (CO_2CH_3), 57.6 (C-9), 63.6 (C-6), 109.1 (C-2), 116.2 (Ar-CH), 120.3 (C-13), 120.9 (Ar-CH), 126.3 (Ar-Cquat.), 126.5 (Ar-Cquat.), 134.9 (Ar-Cquat.), 136.9 (Ar-Cquat.), 163.2 (C-5), 168.5 (CO_2Me), 168.7 (CO_2Me); **m/z** (ES+) 421 ($[\text{M}+\text{Na}]^+$, 100%), **HRMS** (ES+) exact mass calculated for $[\text{M}+\text{Na}]^+$ ($\text{C}_{22}\text{H}_{26}\text{N}_2\text{O}_5\text{Na}^+$) requires m/z 421.1734, found m/z 421.1734.

Preparation and characterisation of diethyl (12bR)-12b-methyl-4-oxo-1,2,6,7,12,12b-hexahydroindolo[2,3-a]quinolizine-3,3(4H)-dicarboxylate (+)-**9e**

Prepared according to general procedure G. Stirred at room temperature for 17 hours then heated at reflux in toluene for 46 hours. The crude mixture was purified by column chromatography on silica gel eluting with petroleum ether/ethyl acetate 4:1 to 3:2 to afford the title product as an off-white solid (69 mg, 86%).



67% e.e. (Chiralcel IA, 90:10 hexane/isopropanol, 1 ml/min, 220 nm, major t_R = 26.3 min, minor t_R = 46.5 min); $[\alpha]_D^{25} = +62.4$ (c 1.76, CHCl_3).


m.p. 93-98 °C; **FT-IR** ν_{max} (NaCl) 3303 cm^{-1} (N-H), 1745 cm^{-1}

(C=O ester), 1731 cm^{-1} (C=O ester), 1629 cm^{-1} (C=O amide); $^1\text{H NMR}$ (CDCl_3 , 500 MHz) δ_{H} 1.17 (t, 3H, $\text{CO}_2\text{CH}_2\text{CH}_3$, J 7.5 Hz), 1.32 (t, 3H, $\text{CO}_2\text{CH}_2\text{CH}_3$, J 7.5 Hz), 1.73 (s, 3H, H-10), 2.01 (app. td, 1H, H-8a, J 14.0 Hz, 3.0 Hz), 2.25 (ddd, 1H, H-8b, J 14.0 Hz, 6.0 Hz, 3.0 Hz), 2.53 (ddd, 1H, H-7a, J 13.5 Hz, 5.5 Hz, 3.0 Hz), 2.65 (app. td, 1H, H-7b, J 13.0 Hz, 3.0 Hz), 2.76 (ddd, 1H, H-3a, J 15.5 Hz, 4.0 Hz, 1.5 Hz), 2.87 (ddd, 1H, H-3b, J 15.5 Hz, 12.0 Hz, 5.5 Hz), 3.12 (app. td, 1H, H-4a, J 12.5 Hz, 4.5 Hz), 4.13-4.38 (m, 4H, $2 \times \text{CO}_2\text{CH}_2\text{CH}_3$), 5.10 (dd, 1H, H-4b, J 13.0 Hz, 4.5 Hz), 7.13 (app. td, 1H, H-13, J 8.0 Hz, 1.0 Hz), 7.20 (app. td, 1H, H-14, J 8.0 Hz, 1.0 Hz), 7.34 (d, 1H, H-15, J 8.0 Hz), 7.50 (d, 1H, H-12, J 8.0 Hz), 8.02 (br s, 1H, NH); $^{13}\text{C NMR}$ (CDCl_3 , 125 MHz) δ_{C} 13.8 ($\text{CO}_2\text{CH}_2\text{CH}_3$), 13.9 ($\text{CO}_2\text{CH}_2\text{CH}_3$), 21.2 (C-3), 25.1 (C-7), 26.9 (C-10), 32.0 (C-8), 37.6 (C-4), 57.5 (C-9), 62.3 ($\text{CO}_2\text{CH}_2\text{CH}_3$), 62.4 ($\text{CO}_2\text{CH}_2\text{CH}_3$), 63.6 (C-6), 108.2 (C-2), 111.1 (C-15), 118.4 (C-12), 119.7 (C-13), 122.1 (C-14), 126.6 (C-11), 136.1 (C-16), 137.4 (C-1), 163.5 (C-5), 168.0 (CO_2Et), 168.2 (CO_2Et); m/z (ES $^-$) 397 ($[\text{M}-\text{H}]^-$, 80%), **HRMS** (ES $^+$) exact mass calculated for $[\text{M}+\text{H}]^+$ ($\text{C}_{22}\text{H}_{27}\text{N}_2\text{O}_5^+$) requires m/z 399.1914, found m/z 399.1913.

Characterisation of diethyl (12bR)-9-bromo-12b-methyl-4-oxo-1,2,6,7,12,12b-hexahydroindolo[2,3-a]quinolizine-3,3(4H)-dicarboxylate (+)-9f

Prepared according to general procedure G. Stirred at room temperature for 31 hours then heated at reflux in toluene for 72 hours. The crude mixture was purified by column chromatography on silica gel eluting with petroleum ether/ethyl acetate 4:1 to 3:2 to afford the title product as an off-white solid (86 mg, 90%).

82% e.e. (Chiralcel OD, 90:10 hexane/isopropanol, 1 ml/min, 220 nm, major t_{R} = 30.3 min, minor t_{R} = 19.9 min); $[\alpha]_{\text{D}}^{25} = +43.5$ (c 1.08, CHCl_3).




m.p. 186-190 $^{\circ}\text{C}$; **FT-IR** $\nu_{\text{max}}(\text{NaCl})$ 3287 cm^{-1} (N-H), 1731 cm^{-1} (2 signals with shoulder, CO_2Me), 1628 cm^{-1} (C=O amide); $^1\text{H NMR}$ (CDCl_3 , 500 MHz) δ_{H} 1.16 (t, 3H, $\text{CO}_2\text{CH}_2\text{CH}_3$, J 7.0 Hz), 1.30 (t, 3H, $\text{CO}_2\text{CH}_2\text{CH}_3$, J 7.0 Hz), 1.74 (s, 3H, H-10), 1.94-2.04 (m, 1H, H-7a), 2.24-2.33 (m, 1H, H-7b), 2.52 (ddd, 1H, H-8a, J 13.5 Hz, 5.5 Hz, 3.0 Hz), 2.60-2.73 (m, 2H, H-3a, H-8b), 2.81 (ddd, 1H, H-3b, J 16.0 Hz, 12.0 Hz, 5.5 Hz), 3.05-3.15 (m, 1H, H-4a), 4.13-4.35 (m, 4H, $2 \times \text{CO}_2\text{CH}_2\text{CH}_3$), 5.07 (dd, 1H, H-4b, J 13.0 Hz, 4.5 Hz), 7.18-7.27 (m, 2H, H-14, H-15), 7.60 (s, 1H, H-12), 8.76 (br s, 1H, NH); $^{13}\text{C NMR}$ (CDCl_3 , 125 MHz) δ_{C} 13.8 & 13.9 ($2 \times \text{CO}_2\text{CH}_2\text{CH}_3$), 21.0 (C-3), 25.0 (C-8), 26.9 (C-10), 32.0 (C-7),

37.5 (C-4), 57.4 (C-9), 62.4 (2 signals, $2 \times \text{CO}_2\text{CH}_2\text{CH}_3$), 63.6 (C-6), 108.0 (C-2), 112.6 (C-14), 112.9 (C-13), 121.1 (C-12), 124.9 (C-15), 128.4 (C-11), 134.8 (C-16), 138.7 (C-1), 163.5 (C-5), 167.9 (CO_2Et), 168.1 (CO_2Et); **m/z** (ES⁻) 475, 477 ($[\text{M}-\text{H}]^-$, 20%), 511, 513 ($[\text{M}+\text{Cl}]^-$, 40%), **HRMS** (ES⁺) exact mass calculated for $[\text{M}+\text{Na}]^+$ ($\text{C}_{22}\text{H}_{25}\text{N}_2\text{O}_5\text{BrNa}^+$) requires **m/z** 499.0839 & 501.0820, found **m/z** 499.0836 & 501.0814.

Characterisation of diethyl (12b*R*)-11,12b-dimethyl-4-oxo-1,2,6,7,12,12b-hexahydroindolo[2,3-*a*]quinolizine-3,3(4*H*)-dicarboxylate (+)-9g

Prepared according to general procedure G. Stirred at room temperature for 20 hours then heated at reflux in toluene for 60 hours. The crude mixture was purified by column chromatography on silica gel eluting with petroleum ether/ethyl acetate 4:1 to 3:1 to afford the title product as an off-white solid (69 mg, 83%).

62% e.e. (Chiralcel AD, 90:10 hexane/isopropanol, 1 ml/min, 220 nm, major t_R = 19.6 min, minor t_R = 26.0 min); $[\alpha]_D^{25} = +71.3$ (c 2.23, CHCl_3).




m.p. 101-106 °C; **FT-IR** ν_{max} (NaCl) 3318 cm^{-1} (N-H), 1744 cm^{-1} (C=O ester), 1732 cm^{-1} (C=O ester), 1630 cm^{-1} (C=O amide), 751 cm^{-1} (ArC-H OOP); **¹H NMR** (CDCl_3 , 400 MHz) δ_H 1.18 (t, 3H, $\text{CO}_2\text{CH}_2\text{CH}_3$, J 7.0 Hz), 1.32 (t, 3H, $\text{CO}_2\text{CH}_2\text{CH}_3$, J 7.0 Hz), 1.75 (s, 3H, H-10), 1.97-2.10 (m, 1H, H-8a), 2.32 (ddd, 1H, H-8b, J 14.0 Hz, 5.5 Hz, 2.5 Hz), 2.46-2.59 (m, 4H, H-16, H-7a), 2.66 (app. td, 1H, H-7b, J 13.5 Hz, 2.5 Hz), 2.75 (app. dd, 1H, H-3a, J 15.5 Hz, 3.5 Hz), 2.86 (ddd, 1H, H-3b, J 16.5 Hz, 11.5 Hz, 5.0 Hz), 3.12 (app. td, 1H, H-4a, J 12.5 Hz, 4.0 Hz), 4.15-4.38 (m, 4H, $2 \times \text{CO}_2\text{CH}_2\text{CH}_3$), 5.09 (dd, 1H, H-4b, J 12.5 Hz, 4.5 Hz), 7.00 (d, 1H, H-14, J 7.0 Hz), 7.07 (app. t, 1H, H-13, J 7.0 Hz), 7.36 (d, 1H, H-12, J 7.5 Hz), 8.11 (br s, 1H, NH); **¹³C NMR** (CDCl_3 , 125 MHz) δ_C 13.8 ($\text{CO}_2\text{CH}_2\text{CH}_3$), 13.9 ($\text{CO}_2\text{CH}_2\text{CH}_3$), 16.7 (C-16), 21.2 (C-3), 25.1 (C-7), 27.0 (C-10), 32.1 (C-8), 37.5 (C-4), 57.5 (C-9), 62.2 ($\text{CO}_2\text{CH}_2\text{CH}_3$), 62.3 ($\text{CO}_2\text{CH}_2\text{CH}_3$), 63.6 (C-6), 108.9 (C-2), 116.1 (C-12), 120.0 (C-13), 120.2 (C-15), 122.8 (C-14), 126.2 (C-11), 135.6 (C-17), 137.1 (C-1), 163.4 (C-5), 167.9 (CO_2Et), 168.2 (CO_2Et); **m/z** (ES⁻) 411 ($[\text{M}-\text{H}]^-$, 100%), **HRMS** (ES⁺) exact mass calculated for $[\text{M}+\text{H}]^+$ ($\text{C}_{23}\text{H}_{29}\text{N}_2\text{O}_5^+$) requires **m/z** 413.2071, found **m/z** 413.2074.

Characterisation of dimethyl (12b*R*)-12b-ethyl-4-oxo-1,2,6,7,12,12b-hexahydroindolo[2,3-*a*]quinolizine-3,3(4*H*)-dicarboxylate (+)-9h

Prepared according to general procedure G. Remark: xylene was used as solvent instead of toluene.

Stirred at room temperature for 48 hours then heated at reflux in xylene for 7 days. The crude mixture was purified by column chromatography on silica gel eluting with petroleum ether/ethyl acetate 4:1 to 3:2 to afford the title product as a pale yellow oil (64 mg, 83%).



71% e.e. (Chiralcel IA, 85:15 hexane/isopropanol, 1 ml/min, 220 nm, major t_R = 12.6 min, minor t_R = 21.6 min); $[\alpha]_D^{25} = +78.9$ (c 0.96, CHCl₃).

FT-IR $\nu_{\max}$ (NaCl) 3308 cm⁻¹ (N-H), 1749 cm⁻¹ (C=O ester), 1737 cm⁻¹ (C=O ester), 1628 cm⁻¹ (C=O amide), 751 cm⁻¹ (ArC-H


OOP); **¹H NMR** (CDCl₃, 500 MHz) δ_H 0.99 (t, 3H, H-11, J 7.5 Hz), 1.96-2.14 (m, 3H, H-8a, H-10), 2.22 (ddd, 1H, H-8b, J 13.5 Hz, 10.5 Hz, 3.0 Hz), 2.32 (ddd, 1H, H-7a, J 13.5 Hz, 10.5 Hz, 3.0 Hz), 2.51 (ddd, 1H, H-7b, J 13.5 Hz, 8.0 Hz, 3.0 Hz), 2.73 (dd, 1H, H-3a, J 15.5 Hz, 3.5 Hz), 2.97 (ddd, 1H, H-3b, J 15.5 Hz, 12.0 Hz, 6.0 Hz), 3.20 (app. td, 1H, H-4a, J 12.5 Hz, 4.5 Hz), 3.72 (s, 3H, CO₂CH₃), 3.86 (s, 3H, CO₂CH₃), 5.01 (dd, 1H, H-4b, J 13.0 Hz, 5.0 Hz), 7.13 (app. td, 1H, H-14, J 7.5 Hz, 1.0 Hz), 7.20 (app. td, 1H, H-15, J 7.5 Hz, 1.0 Hz), 7.35 (d, 1H, H-16, J 8.0 Hz), 7.51 (d, 1H, H-13, J 8.0 Hz), 8.15 (br s, 1H, NH); **¹³C NMR** (CDCl₃, 125 MHz) δ_C 8.7 (C-11), 20.8 (C-3), 25.0 (C-7), 27.8 (C-8), 33.4 (C-10), 37.4 (C-4), 53.3 (CO₂CH₃), 53.3 (CO₂CH₃), 61.3 (C-9), 63.8 (C-6), 109.3 (C-2), 111.0 (C-16), 118.4 (C-13), 119.8 (C-14), 122.2 (C-15), 126.9 (C-12), 135.1 (C-17), 136.5 (C-1), 164.4 (C-5), 168.3 (CO₂Me), 168.7 (CO₂Me); ***m/z*** (ES⁻) 383 ([M-H]⁻, 100%), **HRMS** (ES⁺) exact mass calculated for [M+Na]⁺ (C₂₁H₂₄N₂O₅Na⁺) requires ***m/z*** 407.1577, found ***m/z*** 407.1576.

Characterisation of diethyl (12b*R*)-12b-ethyl-4-oxo-1,2,6,7,12,12b-hexahydroindolo[2,3-*a*]quinolizine-3,3(4*H*)-dicarboxylate (+)-9i

Prepared according to general procedure G. Remark: xylene was used as solvent instead of toluene.

Stirred at room temperature for 48 hours then heated at reflux in xylene for 4 days. The crude mixture was purified by column chromatography on silica gel eluting with petroleum ether/ethyl acetate 4:1 to 2:1 to afford the title product as a pale yellow oil (60 mg, 73%).

76% e.e. (Chiralcel AD, 80:20 hexane/isopropanol, 1 ml/min, 220 nm, major t_R = 8.1 min, minor t_R = 18.8 min); $[\alpha]_D^{25} = +86.6$ (c 1.12, CHCl_3).




FT-IR ν_{max} (NaCl) 3308 cm^{-1} (N-H), 1746 cm^{-1} (C=O ester), 1733 cm^{-1} (C=O ester), 1629 cm^{-1} (C=O amide), 748 cm^{-1} (ArC-H OOP); **^1H NMR** (CDCl_3 , 500 MHz) δ_{H} 1.00 (t, 3H, H-11, J 7.5 Hz), 1.19 (t, 3H, $\text{CO}_2\text{CH}_2\text{CH}_3$, J 7.0 Hz), 1.34 (t, 3H, $\text{CO}_2\text{CH}_2\text{CH}_3$, J 7.0 Hz), 1.94-2.13 (m, 3H, H-8a, H-10), 2.23 (ddd, 1H, H-8b, J 13.0 Hz, 10.0 Hz, 3.0 Hz), 2.31 (ddd, 1H, H-7a, J 13.0 Hz, 10.0 Hz, 3.0 Hz), 2.51 (ddd, 1H, H-7b, J 13.0 Hz, 8.5 Hz, 3.0 Hz), 2.72 (app. dd, 1H, H-3a, J 15.5 Hz, 4.0 Hz), 2.95 (ddd, 1H, H-3b, J 15.5 Hz, 12.0 Hz, 6.0 Hz), 3.18 (app. td, 1H, H-4a, J 12.5 Hz, 4.5 Hz), 4.14-4.22 (m, 2H, $\text{CO}_2\text{CH}_2\text{CH}_3$), 4.30-4.36 (m, 2H, $\text{CO}_2\text{CH}_2\text{CH}_3$), 5.02 (dd, 1H, H-4b, J 13.0 Hz, 5.0 Hz), 7.13 (app. td, 1H, H-14, J 7.5 Hz, 1.0 Hz), 7.20 (app. td, 1H, H-15, J 7.5 Hz, 1.0 Hz), 7.34 (d, 1H, H-16, J 8.0 Hz), 7.50 (d, 1H, H-13, J 8.0 Hz), 7.87 (br s, 1H, NH); **^{13}C NMR** (CDCl_3 , 125 MHz) δ_{C} 8.9 (C-11), 13.8 ($\text{CO}_2\text{CH}_2\text{CH}_3$), 14.0 ($\text{CO}_2\text{CH}_2\text{CH}_3$), 20.8 (C-3), 24.9 (C-7), 28.0 (C-8), 33.5 (C-10), 37.4 (C-4), 61.1 (C-9), 62.3 ($\text{CO}_2\text{CH}_2\text{CH}_3$), 62.4 ($\text{CO}_2\text{CH}_2\text{CH}_3$), 63.8 (C-6), 109.5 (C-2), 110.9 (C-16), 118.4 (C-13), 119.8 (C-14), 122.2 (C-15), 126.9 (C-12), 135.8 (C-17), 136.6 (C-1), 164.4 (C-5), 167.8 (CO_2Et), 168.3 (CO_2Et); **m/z** (ES $^-$) 411 ($[\text{M}-\text{H}]^-$, 100%), **HRMS** (ES $^+$) exact mass calculated for $[\text{M}+\text{Na}]^+$ ($\text{C}_{23}\text{H}_{28}\text{N}_2\text{O}_5\text{Na}^+$) requires m/z 435.1890, found m/z 435.1891.

Characterisation of dimethyl (12bR)-12b-ethyl-11-methyl-4-oxo-1,2,6,7,12,12b-hexahydroindolo[2,3-a]quinolizine-3,3(4H)-dicarboxylate (+)-**9j**

Prepared according to general procedure G. Remark: xylene was used as solvent instead of toluene.

Stirred at room temperature for 48 hours then heated at reflux in xylene for 10 days. The crude mixture was purified by chromatography on silica gel eluting with petroleum ether/ethyl acetate 4:1 to 3:2 to afford the title product as a pale yellow oil (48 mg, 60%).



75% e.e. (Chiralcel AD, 80:20 hexane/isopropanol, 1 ml/min, 220 nm, major t_R = 7.8 min, minor t_R = 12.5 min); $[\alpha]_D^{25} = +112.4$ (c 1.40, CHCl_3).


FT-IR ν_{max} (NaCl) 3327 cm^{-1} (N-H), 1748 cm^{-1} (C=O ester), 1737 cm^{-1} (C=O ester), 1629 cm^{-1} (C=O amide), 751 cm^{-1} (ArC-H

OOP); **¹H NMR** (CDCl₃, 500 MHz) δ_{H} 1.00 (t, 3H, H-11, *J* 7.5 Hz), 1.99 (dq, 1H, H-10a, *J* 14.5 Hz, 7.5 Hz), 2.06-3.14 (m, 2H, H-8a, H-10b), 2.23 (ddd, 1H, H-8b, *J* 13.5 Hz, 10.5 Hz, 3.0 Hz), 2.32 (ddd, 1H, H-7a, *J* 13.5 Hz, 10.5 Hz, 3.0 Hz), 2.47-2.55 (m, 4H, H-7b, H-17), 2.71 (dd, 1H, H-3a, *J* 15.5 Hz, 4.0 Hz), 2.97 (ddd, 1H, H-3b, *J* 15.5 Hz, 12.0 Hz, 6.0 Hz), 3.18 (app. td, 1H, H-4a, *J* 12.5 Hz, 4.5 Hz), 3.73 (s, 3H, CO₂CH₃), 3.87 (s, 3H, CO₂CH₃), 5.01 (dd, 1H, H-4b, *J* 13.0 Hz, 5.5 Hz), 7.02 (d, 1H, H-15, *J* 7.5 Hz), 7.07 (t, 1H, H-14, *J* 7.5 Hz), 7.36 (d, 1H, H-13, *J* 8.0 Hz), 7.65 (br s, 1H, NH); **¹³C NMR** (CDCl₃, 125 MHz) δ_{C} 8.7 (C-11), 16.7 (C-17), 20.9 (C-3), 25.0 (C-7), 27.9 (C-8), 33.5 (C-10), 37.4 (C-4), 53.3 (CO₂CH₃), 53.3 (CO₂CH₃), 61.3 (C-9), 63.8 (C-6), 110.1 (C-2), 116.1 (C-13), 120.1 (2C, C-14, C-16), 123.0 (C-15), 126.5 (C-12), 135.3 (C-18), 136.2 (C-1), 164.3 (C-5), 168.3 (CO₂Me), 168.7 (CO₂Me); ***m/z*** (ES[−]) 397 ([M−H][−], 100%), **HRMS** (ES⁺) exact mass calculated for [M+Na]⁺ (C₂₂H₂₆N₂O₅Na⁺) requires ***m/z*** 421.1734, found ***m/z*** 421.1727.


References

- 1 G. Bartoli, G. Palmieri, M. Bosco and R. Dalpozzo, *Tetrahedron Lett.*, 1989, **30**, 2129-2132.
- 2 C. G. Hartung, A. Fecher, B. Chapell and V. Snieckus, *Org. Lett.*, 2003, **5**, 1899-1902.
- 3 C. S. Cho, J. H. Kim, T.-J. Kim and S. C. Shim, *Tetrahedron*, 2001, **57**, 3321-3329.
- 4 K. Sako, H. Aoyama, S. Sato, Y. Hashimoto and M. Baba, *Bioorg. Med. Chem.*, 2008, **16**, 3780-3790.
- 5 M. E. Muratore, C. A. Holloway, A. W. Pilling, R. I. Storer, G. Trevitt and D. J. Dixon, *J. Am. Chem. Soc.*, 2009, **131**, 10796-10797.
- 6 J. Franzén and A. Fischer, *Angew. Chem. Int. Ed.*, 2009, **48**, 787-791.
- 7 Y. Torisawa, A. Hashimoto, M. Nakagawa, H. Seki, R. Hara and T. Hino, *Tetrahedron*, 1991, **47**, 8067-8078.
- 8 C. A. Holloway, M. E. Muratore, R. I. Storer, G. Trevitt and D. J. Dixon, *Org. Lett.*, 2010, **131**, 10796-10797.


¹H NMR spectrum of 7-methyl-1*H*-indole 10a




¹³C NMR spectrum of 7-methyl-1*H*-indole 10a




¹H NMR spectrum of 7-ethyl-1*H*-indole 10b




¹³C NMR spectrum of 7-ethyl-1*H*-indole 10b




¹H NMR spectrum of 7-methyl-3-[(*E*)-2-nitrovinyl]-1*H*-indole 12a




¹³C NMR spectrum of 7-methyl-3-[(*E*)-2-nitrovinyl]-1*H*-indole 12a




¹H NMR spectrum of 7-ethyl-3-[(*E*)-2-nitrovinyl]-1*H*-indole 12b




¹³C NMR spectrum of 7-ethyl-3-[(*E*)-2-nitrovinyl]-1*H*-indole 12b




¹H NMR spectrum of 2-(7-methyl-1*H*-indol-3-yl)ethanamine 13c




¹³C NMR spectrum of 2-(7-methyl-1*H*-indol-3-yl)ethanamine 13c




¹H NMR spectrum of 2-(7-ethyl-1*H*-indol-3-yl)ethanamine 13d




¹³C NMR spectrum of 2-(7-ethyl-1*H*-indol-3-yl)ethanamine 13d




¹H NMR spectrum of methyl 3-{{2-(1*H*-indol-3-yl)ethyl}amino}-3-oxopropanoate 14a




¹³C NMR spectrum of methyl 3-{{2-(1*H*-indol-3-yl)ethyl}amino}-3-oxopropanoate 14a




¹H NMR spectrum of methyl 3-([2-(5-bromo-1*H*-indol-3-yl)ethyl]amino)-3-oxopropanoate 14b




¹³C NMR spectrum of methyl 3-([2-(5-bromo-1*H*-indol-3-yl)ethyl]amino)-3-oxopropanoate 14b




¹H NMR spectrum of methyl 3-([2-(7-methyl-1*H*-indol-3-yl)ethyl]amino)-3-oxopropanoate 14c




¹³C NMR spectrum of methyl 3-([2-(7-methyl-1*H*-indol-3-yl)ethyl]amino)-3-oxopropanoate 14c




¹H NMR spectrum of methyl 3-{{2-(7-ethyl-1*H*-indol-3-yl)ethyl}amino}-3-oxopropanoate 14d




¹³C NMR spectrum of methyl 3-{{2-(7-ethyl-1*H*-indol-3-yl)ethyl}amino}-3-oxopropanoate 14d




¹H NMR spectrum of ethyl 3-{[2-(1*H*-indol-3-yl)ethyl]amino}-3-oxopropanoate 14e




¹³C NMR spectrum of ethyl 3-{[2-(1*H*-indol-3-yl)ethyl]amino}-3-oxopropanoate 14e




¹H NMR spectrum of ethyl 3-{[2-(5-bromo-1*H*-indol-3-yl)ethyl]amino}-3-oxopropanoate 14f




¹³C NMR spectrum of ethyl 3-{[2-(5-bromo-1*H*-indol-3-yl)ethyl]amino}-3-oxopropanoate 14f




¹H NMR spectrum of ethyl 3-{[2-(7-methyl-1*H*-indol-3-yl)ethyl]amino}-3-oxopropanoate 14g




¹³C NMR spectrum of ethyl 3-{[2-(7-methyl-1*H*-indol-3-yl)ethyl]amino}-3-oxopropanoate 14g




¹H NMR spectrum of dimethyl {[2-(1*H*-indol-3-yl)ethyl]carbamoyl}malonate 6a




¹³C NMR spectrum of dimethyl {[2-(1*H*-indol-3-yl)ethyl]carbamoyl}malonate 6a




¹H NMR spectrum of dimethyl {[2-(5-bromo-1*H*-indol-3-yl)ethyl]carbamoyl}malonate 6b




¹³C NMR spectrum of dimethyl {[2-(5-bromo-1*H*-indol-3-yl)ethyl]carbamoyl}malonate 6b




¹H NMR spectrum of dimethyl {[2-(7-methyl-1*H*-indol-3-yl)ethyl]carbamoyl}malonate 6c




¹³C NMR spectrum of dimethyl {[2-(7-methyl-1*H*-indol-3-yl)ethyl]carbamoyl}malonate 6c




¹H NMR spectrum of dimethyl {[2-(7-ethyl-1*H*-indol-3-yl)ethyl]carbamoyl}malonate 6d




¹³C NMR spectrum of dimethyl {[2-(7-ethyl-1*H*-indol-3-yl)ethyl]carbamoyl}malonate 6d




¹H NMR spectrum of diethyl {[2-(1*H*-indol-3-yl)ethyl]carbamoyl}malonate 6e




¹³C NMR spectrum of diethyl {[2-(1*H*-indol-3-yl)ethyl]carbamoyl}malonate 6e




¹H NMR spectrum of diethyl {[2-(5-bromo-1*H*-indol-3-yl)ethyl]carbamoyl}malonate 6f




¹³C NMR spectrum of diethyl {[2-(5-bromo-1*H*-indol-3-yl)ethyl]carbamoyl}malonate 6f




¹H NMR spectrum of diethyl {[2-(7-methyl-1*H*-indol-3-yl)ethyl]carbamoyl}malonate 6g




¹³C NMR spectrum of diethyl {[2-(7-methyl-1*H*-indol-3-yl)ethyl]carbamoyl}malonate 6g




¹H NMR spectrum of dimethyl {[2-(1*H*-indol-3-yl)ethyl]carbamoyl}(3-oxobutyl)malonate 8a




¹H NMR spectrum of dimethyl {[2-(1*H*-indol-3-yl)ethyl]carbamoyl}(3-oxobutyl)malonate 8a





¹H NMR spectrum of dimethyl (12b*R*)-12b-methyl-4-oxo-1,2,6,7,12,12b-hexahydroindolo[2,3-*a*]quinolizine-3,3(4*H*)-dicarboxylate 9a



¹³C NMR spectrum of dimethyl (12b*R*)-12b-methyl-4-oxo-1,2,6,7,12,12b-hexahydroindolo[2,3-*a*]quinolizine-3,3(4*H*)-dicarboxylate 9a



HPLC trace of racemic β -carboline ($\pm$)-9a





Area Percent Report

Sorted By : Signal
Multiplier: : 1.0000
Dilution: : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 C, Sig=220,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	14.078	MM	0.7669	4287.07764	93.17085	50.5384
2	17.127	MM	1.0253	4195.74170	68.20614	49.4616

HPLC trace of enantioenriched β -carboline (+)-9a




Area Percent Report

Sorted By : Signal
Multiplier: : 1.0000
Dilution: : 1.0000
Use Multiplier & Dilution Factor with ISTDs


Signal 1: DAD1 C, Sig=220,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	13.709	MM	0.8148	1746.14075	35.71588	22.2085
2	16.728	MM	1.1096	6116.35156	91.87128	77.7915


¹H NMR spectrum of dimethyl (12b*R*)-9-bromo-12b-methyl-4-oxo-1,2,6,7,12,12b-hexahydroindolo[2,3-*a*]quinolizine-3,3(4*H*)-dicarboxylate 9b




¹³C NMR spectrum of dimethyl (12b*R*)-9-bromo-12b-methyl-4-oxo-1,2,6,7,12,12b-hexahydroindolo[2,3-*a*]quinolizine-3,3(4*H*)-dicarboxylate 9b



HPLC trace of racemic β -carboline ($\pm$)-9b



Current Chromatogram(s)





Signal 4: DAD1 D, Sig=220,16 Ref=400,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.768	VB	0.4601	6.54765e4	2097.87866	49.4743
2	14.313	MM	1.2998	6.68678e4	857.38068	50.5257

Totals : 1.32344e5 2955.25934

HPLC trace of enantioenriched β -carboline (+)-9b




Signal 3: DAD1 C, Sig=220,8 Ref=360,100


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	14.076	MM	0.6536	1.43574e4	366.11453	88.6088
2	42.794	MM	1.9682	1845.73328	15.62994	11.3912

Totals : 1.62031e4 381.74448



¹H NMR spectrum of dimethyl (12b*R*)-11,12b-dimethyl-4-oxo-1,2,6,7,12,12b-hexahydroindolo[2,3-*a*]quinolizine-3,3(4*H*)-dicarboxylate 9c



¹³C NMR spectrum of dimethyl (12b*R*)-11,12b-dimethyl-4-oxo-1,2,6,7,12,12b-hexahydroindolo[2,3-*a*]quinolizine-3,3(4*H*)-dicarboxylate 9c



HPLC trace of racemic β -carboline ($\pm$)-9c





Area Percent Report

Sorted By : Signal
Multiplier: : 1.0000
Dilution: : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 C, Sig=220,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	24.813	MF	1.6818	3.72201e4	368.84409	50.5727
2	31.406	FM	2.1498	3.63771e4	282.01553	49.4273

HPLC trace of enantioenriched β -carboline (+)-9c




Area Percent Report

Sorted By : Signal
Multiplier: : 1.0000
Dilution: : 1.0000
Use Multiplier & Dilution Factor with ISTDs


Signal 1: DAD1 C, Sig=220,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	25.576	MM	1.5854	3014.53564	31.69057	17.0432
2	31.635	MM	2.0636	1.46731e4	118.50961	82.9568



¹H NMR spectrum of dimethyl (12b*R*)-11-ethyl-12b-methyl-4-oxo-1,2,6,7,12,12b-hexahydroindolo[2,3a]quinolizine-3,3(4*H*)-dicarboxylate 9d



¹³C NMR spectrum of dimethyl (12b*R*)-11-ethyl-12b-methyl-4-oxo-1,2,6,7,12,12b-hexahydroindolo[2,3a]quinolizine-3,3(4*H*)-dicarboxylate 9d



HPLC trace of racemic β -carboline ($\pm$)-9d





Area Percent Report

Sorted By : Signal
Multiplier: : 1.0000
Dilution: : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 D, Sig=220,16 Ref=400,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	19.578	MM	1.1721	4.36764e4	621.06903	50.6549
2	24.259	MM	1.3499	4.25470e4	525.29303	49.3451

HPLC trace of enantioenriched β -carboline (+)-9d




Area Percent Report

Sorted By : Signal
Multiplier: : 1.0000
Dilution: : 1.0000
Use Multiplier & Dilution Factor with ISTDs


Signal 1: DAD1 C, Sig=220,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	18.682	MM	1.1689	3989.46143	56.88504	16.2138
2	23.080	MM	1.5404	2.06159e4	223.05655	83.7862



¹H NMR spectrum of diethyl (12b*R*)-12b-methyl-4-oxo-1,2,6,7,12,12b-hexahydroindolo[2,3-*a*]quinolizine-3,3(4*H*)-dicarboxylate 9e



¹³C NMR spectrum of diethyl (12b*R*)-12b-methyl-4-oxo-1,2,6,7,12,12b-hexahydroindolo[2,3-*a*]quinolizine-3,3(4*H*)-dicarboxylate 9e



HPLC trace of racemic β -carboline ($\pm$)-9e





Area Percent Report

Sorted By : Signal
Multiplier: : 1.0000
Dilution: : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 B, Sig=220,16 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	23.429	MM	1.0712	1.46327e4	227.65962	50.0479
2	41.947	MM	2.9263	1.46047e4	83.18184	49.9521

HPLC trace of enantioenriched β -carboline (+)-9e




Area Percent Report

Sorted By : Signal
Multiplier: : 1.0000
Dilution: : 1.0000
Use Multiplier & Dilution Factor with ISTDs


Signal 1: DAD1 B, Sig=220,16 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	26.315	MM	1.4240	3.48783e4	408.20990	83.4394
2	48.526	MM	2.5241	6922.46338	45.70938	16.5606



¹H NMR spectrum of diethyl (12b*R*)-9-bromo-12b-methyl-4-oxo-1,2,6,7,12,12b-hexahydroindolo[2,3-*a*]quinolizine-3,3(4*H*)-dicarboxylate 9f



¹³C NMR spectrum of diethyl (12b*R*)-9-bromo-12b-methyl-4-oxo-1,2,6,7,12,12b-hexahydroindolo[2,3-*a*]quinolizine-3,3(4*H*)-dicarboxylate 9f



HPLC trace of racemic β -carboline ($\pm$)-9f





Area Percent Report

Sorted By : Signal
Multiplier: : 1.0000
Dilution: : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 C, Sig=220,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	19.155	MM	1.3088	3898.58789	49.64620	49.7894
2	30.331	MM	1.8383	3931.57251	35.64463	50.2106

HPLC trace of enantioenriched β -carboline (+)-9f




Area Percent Report

Sorted By : Signal
Multiplier: 1.0000
Dilution: 1.0000
Use Multiplier & Dilution Factor with ISTDs


Signal 1: DAD1 C, Sig=220,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	19.875	MM	1.4031	5512.52783	65.47871	8.8378
2	30.375	MM	1.9878	5.68620e4	476.76862	91.1622



¹H NMR spectrum of diethyl (12bR)-11,12b-dimethyl-4-oxo-1,2,6,7,12,12b-hexahydroindolo[2,3-a]quinolizine-3,3(4H)-dicarboxylate 9g



¹³C NMR spectrum of diethyl (12bR)-11,12b-dimethyl-4-oxo-1,2,6,7,12,12b-hexahydroindolo[2,3-a]quinolizine-3,3(4H)-dicarboxylate 9g



HPLC trace of racemic β -carboline ($\pm$)-9g





Area Percent Report

Sorted By : Signal
Multiplier: : 1.0000
Dilution: : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 C, Sig=220,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	2.788	BV	0.2324	332.81735	19.18505	0.9233
2	3.251	VB	0.2119	27.81184	1.88751	0.0772
3	20.070	BB	1.1832	1.78855e4	237.33351	49.6172
4	25.810	BB	1.3770	1.78008e4	199.49512	49.3824

HPLC trace of enantioenriched β -carboline (+)-9g




Area Percent Report

Sorted By : Signal
Multiplier: 1.0000
Dilution: 1.0000
Use Multiplier & Dilution Factor with ISTDs


Signal 1: DAD1 C, Sig=220,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	19.625	MM	0.8889	1.27767e4	239.56836	81.0719
2	25.991	MM	1.1065	2983.01831	44.93362	18.9281



¹H NMR spectrum of dimethyl (12b*R*)-12b-ethyl-4-oxo-1,2,6,7,12,12b-hexahydroindolo[2,3-*a*]quinolizine-3,3(4*H*)-dicarboxylate 9h



¹³C NMR spectrum of dimethyl (12b*R*)-12b-ethyl-4-oxo-1,2,6,7,12,12b-hexahydroindolo[2,3-*a*]quinolizine-3,3(4*H*)-dicarboxylate 9h



HPLC trace of racemic β -carboline ($\pm$)-9h





Area Percent Report

Sorted By : Signal
Multiplier: : 1.0000
Dilution: : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 C, Sig=220,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	13.552	MM	0.6535	7290.93115	185.94194	49.9827
2	21.863	MM	1.3643	7295.96777	89.12964	50.0173

HPLC trace of enantioenriched β -carboline (+)-9h





Area Percent Report

Sorted By : Signal
Multiplier: : 1.0000
Dilution: : 1.0000
Use Multiplier & Dilution Factor with ISTDs



Signal 1: DAD1 C, Sig=220,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	12.562	FM	0.7461	1.38525e4	309.43198	85.4141
2	21.636	MM	1.2300	2365.55811	32.05275	14.5859



¹H NMR spectrum of diethyl (12b*R*)-12b-ethyl-4-oxo-1,2,6,7,12,12b-hexahydroindolo[2,3-*a*]quinolizine-3,3(4*H*)-dicarboxylate 9i



¹³C NMR spectrum of diethyl (12b*R*)-12b-ethyl-4-oxo-1,2,6,7,12,12b-hexahydroindolo[2,3-*a*]quinolizine-3,3(4*H*)-dicarboxylate 9i



HPLC trace of racemic β -carboline ($\pm$)-9i





Area Percent Report

Sorted By : Signal
Multiplier: : 1.0000
Dilution: : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 C, Sig=220,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.006	MM	0.3264	3196.87256	163.24565	50.2564
2	18.072	MM	0.8300	3164.25732	63.53744	49.7436

HPLC trace of enantioenriched β -carboline (+)-9i




Area Percent Report

Sorted By : Signal
Multiplier: : 1.0000
Dilution: : 1.0000
Use Multiplier & Dilution Factor with ISTDs


Signal 1: DAD1 C, Sig=220,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.076	MM	0.3330	1.14520e4	573.11499	88.2150
2	18.804	MM	0.8726	1529.92029	29.22136	11.7850



¹H NMR spectrum of dimethyl (12b*R*)-12b-ethyl-11-methyl-4-oxo-1,2,6,7,12,12b-hexahydroindolo[2,3-*a*]quinolizine-3,3(4*H*)-dicarboxylate 9j



¹³C NMR spectrum of dimethyl (12b*R*)-12b-ethyl-11-methyl-4-oxo-1,2,6,7,12,12b-hexahydroindolo[2,3-*a*]quinolizine-3,3(4*H*)-dicarboxylate 9j



HPLC trace of racemic β -carboline ($\pm$)-9j





Area Percent Report

Sorted By : Signal
Multiplier: : 1.0000
Dilution: : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 C, Sig=220,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.104	VB	0.3603	2.31584e4	999.51569	50.0747
2	13.386	BB	0.6211	2.30893e4	569.34216	49.9253

HPLC trace of enantioenriched β -carboline (+)-9j



Area Percent Report

Sorted By : Signal
Multiplier: : 1.0000
Dilution: : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 C, Sig=220,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.822	MM	0.3908	1.33492e4	569.25592	87.3990
2	12.460	MM	0.6170	1924.66101	51.98965	12.6010